LG Chem, Ltd.

Republic of Korea

Back to Profile

1-100 of 114 for LG Chem, Ltd. Sort by
Query
Patent
Canada - CIPO
Excluding Subsidiaries
Aggregations Reset Report
Date
2024 (YTD) 4
2023 24
2022 31
2021 10
2020 14
See more
IPC Class
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics 20
A61P 3/04 - Anorexiants; Antiobesity agents 16
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol 13
A61P 15/10 - Drugs for genital or sexual disorders; Contraceptives for impotence 10
C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms 10
See more
Status
Pending 79
Registered / In Force 35
Found results for  patents
  1     2        Next Page

1.

METHANE-REFORMING CATALYST AND PREPARATION METHOD THEREFOR

      
Document Number 03241046
Status Pending
Filing Date 2023-09-12
Open to Public Date 2024-04-25
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Kim, Yongseon
  • Cho, Jun Yeon
  • Choi, Jae Soon
  • Choi, Jun Seon
  • Kim, Sangjin
  • Kim, Sojin
  • Kim, Suji
  • Choi, Hyun A

Abstract

A methane-reforming catalyst according to one embodiment of the present application comprises: a porous metal support; a first coating layer, which is provided on the porous metal support and comprises an inorganic oxide; and a second coating layer, which is provided on the first coating layer and comprises a perovskite-based compound represented by chemical formula 1, wherein the inorganic oxide comprises CeO2 or Al2O3.

IPC Classes  ?

  • B01J 21/02 - Boron or aluminium; Oxides or hydroxides thereof
  • B01J 21/06 - Silicon, titanium, zirconium or hafnium; Oxides or hydroxides thereof
  • B01J 23/00 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group
  • B01J 23/02 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of the alkali- or alkaline earth metals or beryllium
  • B01J 23/10 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of rare earths
  • B01J 23/755 - Nickel
  • B01J 37/02 - Impregnation, coating or precipitation
  • B01J 37/08 - Heat treatment
  • C01B 3/40 - Production of hydrogen or of gaseous mixtures containing hydrogen by reaction of gaseous or liquid organic compounds with gasifying agents, e.g. water, carbon dioxide, air by reaction of hydrocarbons with gasifying agents using catalysts characterised by the catalyst

2.

METHOD FOR PREPARING ISOPROPYL ALCOHOL

      
Document Number 03237292
Status Pending
Filing Date 2023-05-25
Open to Public Date 2024-02-29
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Hwang, Sung June
  • Lee, Sung Kyu
  • Jang, Kyung Soo
  • Lim, Kil Taek

Abstract

Provided is a method for preparing isopropyl alcohol including: (S1) passing reaction water through a first heat exchanger and a second heat exchanger to heat the reaction water, (S2) supplying the reaction water passed through the second heat exchanger to a reactor as a feed stream with a propylene monomer to produce a gaseous reaction product including isopropyl alcohol (IPA), (S3) purifying the isopropyl alcohol from the gaseous reaction product and recovering process water, and (S4) passing the process water through the second heat exchanger to cool the process water, and transferring a portion of the cooled process water to the first heat exchanger, wherein the reaction water is brought into contact with the portion of the cooled process water in the first heat exchanger for primary heating, and then brought into contact with the process water in the second heat exchanger for secondary heating.

IPC Classes  ?

  • C07C 29/04 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by addition of hydroxy groups to unsaturated carbon-to-carbon bonds, e.g. with the aid of H2O2 by hydration of carbon-to-carbon double bonds
  • C07C 29/76 - Separation; Purification; Stabilisation; Use of additives by physical treatment
  • C07C 29/88 - Separation; Purification; Stabilisation; Use of additives by treatment giving rise to a chemical modification of at least one compound
  • C07C 31/10 - Monohydroxylic acyclic alcohols containing three carbon atoms
  • C07C 31/12 - Monohydroxylic acyclic alcohols containing four carbon atoms

3.

METHOD OF PREPARING ISOPROPYL ALCOHOL

      
Document Number 03237588
Status Pending
Filing Date 2023-06-09
Open to Public Date 2024-02-22
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Hwang, Sung June
  • Lee, Sung Kyu
  • Kim, Sung Kyun
  • Jang, Kyung Soo

Abstract

Provided is a method of preparing IPA including a purification step using a plurality of column, in which in a first column, an upper stream including a mixture of IPA, NPA, and water and a lower stream including water and high-boiling point organic substances are separated from a feed stream including IPA, NPA, water, and high-boiling point organic substances, in a second column, a lower stream including IPA and NPA and an upper stream in which a solvent forms a three-component azeotropic mixture with water and IPA are discharged from the upper stream of the first column, using the organic solvent, and in a third dividing wall column, a stream in which a branch stream of the lower stream of the first column and the lower stream of the second column are mixed is supplied to a first area, an upper stream including water from which high-boiling point organic substances have been removed, a side stream including IPA from which NPA has been removed, and a lower stream including the high-boiling point organic substances and NPA are separated from the mixed stream, and the side stream including IPA is recovered from the second area.

IPC Classes  ?

  • C07C 29/88 - Separation; Purification; Stabilisation; Use of additives by treatment giving rise to a chemical modification of at least one compound
  • C07C 29/76 - Separation; Purification; Stabilisation; Use of additives by physical treatment
  • C07C 31/10 - Monohydroxylic acyclic alcohols containing three carbon atoms

4.

METHOD AND APPARATUS FOR PREPARING ISOPROPYL ALCOHOL

      
Document Number 03237786
Status Pending
Filing Date 2023-05-25
Open to Public Date 2024-02-15
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Jang, Kyung Soo
  • Lee, Sung Kyu
  • Hwang, Sung June
  • Lim, Kil Taek

Abstract

The present invention provides a method for preparing isopropyl alcohol, and an apparatus for carrying out the method, the method comprising the steps of: (S1) supplying a feed stream, containing a propylene monomer and water, to a reactor in the presence of a catalyst to perform a gas phase reaction; (S2) partially condensing a reaction product, obtained by means of the gas phase reaction, in a heat exchanger, and then transferring the uncondensed gas phase reaction product to an absorption tower and a portion of the condensed liquid phase reaction product to a pH measurement system connected on-line between the heat exchanger and the absorption tower; (S3) calculating the catalyst content by measuring the pH of the liquid reaction product transferred to the pH measuring system, and supplementing the reactor with the catalyst in an amount corresponding to the calculated content; and (S4) separating isopropyl alcohol contained in the gas phase reaction product in the absorption tower by dissolving the isopropyl alcohol in absorbing water.

IPC Classes  ?

  • C07C 29/03 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by addition of hydroxy groups to unsaturated carbon-to-carbon bonds, e.g. with the aid of H2O2
  • C07C 29/88 - Separation; Purification; Stabilisation; Use of additives by treatment giving rise to a chemical modification of at least one compound
  • C07C 31/10 - Monohydroxylic acyclic alcohols containing three carbon atoms

5.

HIGHLY BRANCHED POLYLACTIDE RESIN AND METHOD FOR PREPARING THE SAME

      
Document Number 03230257
Status Pending
Filing Date 2023-05-26
Open to Public Date 2023-12-14
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Woo, Won Hee
  • Park, Si Jung
  • Choi, Heung Yeal
  • Oh, Wan Kyu

Abstract

The present disclosure has a feature that a specific branching agent, a phosphorus-based compound and an organic acid anhydride are used in the polylactide resin, thereby enabling highly branching of the polylactide resin, which has not been achieved hitherto, and improving several physical properties, especially melt strength, compared to conventional polylactide resins, and it can be applied even to processes that were difficult to apply to conventional polylactide resins such expanded foam.

IPC Classes  ?

  • C08G 63/91 - Polymers modified by chemical after-treatment
  • C08K 5/09 - Carboxylic acids; Metal salts thereof; Anhydrides thereof
  • C08K 5/1515 - Three-membered rings
  • C08K 5/5313 - Phosphinic compounds, e.g. R2=P(:O)OR'
  • C08L 67/04 - Polyesters derived from hydroxy carboxylic acids, e.g. lactones

6.

POSITIVE ELECTRODE ACTIVE MATERIAL AND METHOD FOR MANUFACTURING SAME

      
Document Number 03239761
Status Pending
Filing Date 2023-05-22
Open to Public Date 2023-11-23
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Jung, Won Sig
  • Baek, Hyeon Hui
  • Jung, Yong Jo
  • Kim, Sang Jun
  • Kim, Jong Pil
  • Lee, Eung Ju

Abstract

A positive electrode active material in a form of a single particle includes a lithium transition metal oxide in a form of a single particle, a coating portion containing cobalt which is formed on the lithium transition metal oxide in the form of a single particle, and LiCoO2 in a form of an island which is discontinuously formed on a surface. A ratio of an intensity of a peak ranging from 550 cm-1 to 620 cm-1 corresponding to an Alg vibration mode of LiCoO2 to an intensity of a peak ranging from 500 cm-1 to 600 cm-1 corresponding to an Alg vibration mode of LiNiO2 in a Raman spectrum of the surface is in a range of 0.1 to 1. Also provided is a method of preparing a positive electrode active material in a form of a single particle.

IPC Classes  ?

  • C01G 53/00 - Compounds of nickel
  • H01M 4/505 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese of mixed oxides or hydroxides containing manganese for inserting or intercalating light metals, e.g. LiMn2O4 or LiMn2OxFy
  • H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
  • H01M 4/02 - Electrodes composed of, or comprising, active material
  • H01M 4/36 - Selection of substances as active materials, active masses, active liquids

7.

POSITIVE ELETRODE ACTIVE MATERIAL AND METHOD FOR PRODUCING THE SAME

      
Document Number 03232603
Status Pending
Filing Date 2023-05-22
Open to Public Date 2023-11-23
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Lee, Eung Ju
  • Baek, Hyeon Hui
  • Jeong, Jong Seok
  • Kim, Jong Pil
  • Jung, Won Sig
  • Rhee, Tae Young
  • Choi, Hwan Young

IPC Classes  ?

  • H01M 4/36 - Selection of substances as active materials, active masses, active liquids
  • H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
  • C01G 53/00 - Compounds of nickel
  • H01M 4/02 - Electrodes composed of, or comprising, active material

8.

POSITIVE ELECTRODE ACTIVE MATERIAL, METHOD FOR PREPARING THE SAME, AND POSITIVE ELECTRODE INCLUDING THE SAME

      
Document Number 03238348
Status Pending
Filing Date 2023-05-22
Open to Public Date 2023-11-23
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Jung, Won Sig
  • Park, Hyun Ah
  • Lee, Kang Hyeon
  • Choi, Hwan Young
  • Kim, Jong Pil
  • Lee, Eung Ju

Abstract

The present invention relates to a single-particle positive electrode active material capable of providing a battery having improved initial resistance and lifespan, a method for preparing the same, and a positive electrode including the same, and relates to a single-particle positive electrode active material having a (cos?)2 value of 0.5 or greater wherein ? represents an angle between a long axis of a crystal grain obtained through electron backscatter diffraction (EBSD) analysis and a lithium migration path, a method for preparing the same, and a positive electrode including the same.

IPC Classes  ?

  • H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
  • H01M 4/131 - Electrodes based on mixed oxides or hydroxides, or on mixtures of oxides or hydroxides, e.g. LiCoOx
  • H01M 4/505 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese of mixed oxides or hydroxides containing manganese for inserting or intercalating light metals, e.g. LiMn2O4 or LiMn2OxFy

9.

POSITIVE ELECTRODE ACTIVE MATERIAL AND POSITIVE ELECTRODE INCLUDING SAME

      
Document Number 03239764
Status Pending
Filing Date 2023-05-22
Open to Public Date 2023-11-23
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Jung, Won Sig
  • Kim, Jong Pil
  • Lee, Eung Ju
  • Rhee, Tae Young
  • Choi, Hwan Young

Abstract

The present invention relates to a positive electrode active material capable of achieving a battery with improved initial resistance characteristics and life characteristics and a positive electrode including the same, and to a positive electrode active material in a form of a single particle, wherein, after a positive electrode, which includes a positive electrode active material layer containing 80 wt% or more of the positive electrode active material based on a total weight of the positive electrode active material layer, is rolled such that density of the positive electrode active material layer after the rolling is 2.7 g/cm3 or more, when the positive electrode active material layer is analyzed by X-ray diffraction (XRD), a ratio of an area of a (003) peak to an area of all peaks identified in a 20 range of 10° to 90° satisfies 30% or more, and a positive electrode including the same.

IPC Classes  ?

  • H01M 4/131 - Electrodes based on mixed oxides or hydroxides, or on mixtures of oxides or hydroxides, e.g. LiCoOx
  • H01M 4/505 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese of mixed oxides or hydroxides containing manganese for inserting or intercalating light metals, e.g. LiMn2O4 or LiMn2OxFy
  • H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy

10.

METHOD FOR PREPARING POSITIVE ELECTRODE ACTIVE MATERIAL

      
Document Number 03238078
Status Pending
Filing Date 2023-04-04
Open to Public Date 2023-11-16
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Lee, Woo Ram
  • Kim, Dong Jin
  • Choi, Sang Soon
  • Kim, Jae Geun

Abstract

The present invention pertains to a method for producing a positive electrode active material capable of providing a battery having excellent initial capacity and life characteristics, the method comprising the steps of: (A) preparing a first sintered product by mixing a positive electrode active material precursor, which contains at least 80 mol% of nickel (Ni) on the basis of the total metal content, and a lithium-containing raw material, and then performing a first sintering; and (B) preparing a lithium transition metal oxide by mixing the first sintered product and a nickel compound and then performing a second sintering, wherein the nickel compound is added such that the mol% of nickel contained in the nickel compound is greater than 0.01 mol% and less than 0.15 mol% on the basis of the total number of moles of metals contained in the positive electrode active material precursor.

IPC Classes  ?

  • H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
  • C01G 53/00 - Compounds of nickel
  • H01M 4/02 - Electrodes composed of, or comprising, active material
  • H01M 4/36 - Selection of substances as active materials, active masses, active liquids

11.

COATING THICKNESS MEAESURING APPARATUS AND METHOD

      
Document Number 03222112
Status Pending
Filing Date 2023-04-25
Open to Public Date 2023-11-02
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Lee, Do-Hyun
  • Lee, Seung-Heon

Abstract

Disclosed is a coating thickness measuring apparatus and method.The coating thickness measuring apparatus according to an embodiment of the present disclosure includes a data obtaining unit configured to obtain thickness data indicating a thickness of a coating material applied to a contact portion of a substrate in contact with a coating roll while the substrate coated with the coating material is transported by the coating roll; and a processor configured to create a virtual memory zone having a plurality of storage areas in which correction data is distributed and stored and correct the thickness data based on the correction data pre-stored in a target storage area selected from the plurality of storage areas to generate corrected thickness data.

IPC Classes  ?

  • G01B 5/00 - Measuring arrangements characterised by the use of mechanical techniques
  • G01B 11/06 - Measuring arrangements characterised by the use of optical techniques for measuring length, width, or thickness for measuring thickness
  • G01B 21/04 - Measuring arrangements or details thereof, where the measuring technique is not covered by the other groups of this subclass, unspecified or not relevant for measuring length, width, or thickness by measuring coordinates of points
  • G01B 21/08 - Measuring arrangements or details thereof, where the measuring technique is not covered by the other groups of this subclass, unspecified or not relevant for measuring length, width, or thickness for measuring thickness
  • H01M 4/04 - Processes of manufacture in general

12.

HIGHLY BRANCHED POLYLACTIDE RESIN AND METHOD FOR PREPARING THE SAME

      
Document Number 03225378
Status Pending
Filing Date 2023-04-24
Open to Public Date 2023-11-02
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Park, Si Jung
  • Woo, Won Hee
  • Choi, Heung Yeal
  • Oh, Wan Kyu

Abstract

The present disclosure has a feature that by using a specific branching agent and a phosphorus-based compound and an anhydride-based compound in the polylactide resin, a high degree of branching of the polylactide resin, which has not been achieved hitherto, can be achieved, and it can also be applied to processes that were difficult to apply to conventional polylactide resins such as expanded foam.

IPC Classes  ?

  • C08K 5/549 - Silicon-containing compounds containing silicon in a ring
  • C08G 63/91 - Polymers modified by chemical after-treatment
  • C08K 5/09 - Carboxylic acids; Metal salts thereof; Anhydrides thereof
  • C08K 5/50 - Phosphorus bound to carbon only
  • C08K 5/5435 - Silicon-containing compounds containing oxygen containing oxygen in a ring
  • C08L 67/04 - Polyesters derived from hydroxy carboxylic acids, e.g. lactones

13.

COATING THICKNESS MEASURING DEVICE AND COATING DEVICE INCLUDING THE SAME

      
Document Number 03231328
Status Pending
Filing Date 2023-04-25
Open to Public Date 2023-11-02
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Lee, Do-Hyun
  • Lee, Seung-Heon

Abstract

A coating thickness measuring device according to an aspect of the present invention pertains to a coating thickness measuring device configured to measure the thickness of a coating material applied to a substrate supplied in a state of being wound on a coating roll, and the coating thickness measuring device comprises a coating thickness measuring module comprising: a light application part for applying light to the surface of coating material applied to a wound portion of the substrate around the coating roll, a light acquisition part for acquiring light reflected from the surface of the coating material, and a processor for calculating the thickness of the coating material on the basis of the acquired light.

IPC Classes  ?

  • G01B 11/06 - Measuring arrangements characterised by the use of optical techniques for measuring length, width, or thickness for measuring thickness
  • G01B 21/04 - Measuring arrangements or details thereof, where the measuring technique is not covered by the other groups of this subclass, unspecified or not relevant for measuring length, width, or thickness by measuring coordinates of points
  • H01M 4/04 - Processes of manufacture in general

14.

POSITIVE ELECTRODE ACTIVE MATERIAL, PREPARATION METHOD THEREOF, AND LITHIUM SECONDARY BATTERY INCLUDING THE POSITIVE ELECTRODE ACTIVE MATERIAL

      
Document Number 03237474
Status Pending
Filing Date 2023-04-03
Open to Public Date 2023-10-05
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Jeong, Jin Hoo
  • Jeong, Myung Gi
  • Ju, Jin Wook
  • Lee, Eung Ju
  • Hwang, Joo Kyoung

Abstract

The present invention relates to a cathode active material and, more specifically, to a cathode active material, a preparation method therefor, and a lithium secondary battery comprising same, the cathode active material comprising a lithium composite transition metal oxide in a single particle form, and a cobalt-containing coating part formed on the lithium composite transition metal oxide in a single particle form, wherein the cobalt-containing coating part has, in the direction from the surface of the cathode active material to the center thereof, a phase gradient from a spinel structure to a layered structure.

IPC Classes  ?

  • H01M 4/36 - Selection of substances as active materials, active masses, active liquids
  • H01M 4/505 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese of mixed oxides or hydroxides containing manganese for inserting or intercalating light metals, e.g. LiMn2O4 or LiMn2OxFy
  • H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
  • H01M 10/052 - Li-accumulators
  • H01M 4/02 - Electrodes composed of, or comprising, active material

15.

POROUS INORGANIC PARTICLES, AND COMPOSITE FILLER, AND PRODUCT USING SAME

      
Document Number 03215221
Status Pending
Filing Date 2023-03-06
Open to Public Date 2023-09-28
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Kim, Yunseop
  • Kim, Lucia
  • Kim, Jee Seon

Abstract

The present disclosure relates to a porous inorganic particle which comprises a sintered body of calcium-based particles, and pores distributed in the sintered body, and has a core-shell structure of a core having a high porosity and a shell having a porosity lower than that of the core, wherein the calcium-based particles comprise first calcium-based particles having a maximum diameter of 10 nm to 500 nm, and second calcium-based particles having a maximum diameter of 1 ? to 10 ?, and to a composite fillers and product using the same.

IPC Classes  ?

  • A61K 8/24 - Phosphorus; Compounds thereof
  • A61K 8/72 - Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
  • A61L 27/02 - Inorganic materials
  • A61L 27/12 - Phosphorus-containing materials, e.g. apatite
  • A61L 27/56 - Porous or cellular materials
  • A61Q 19/00 - Preparations for care of the skin
  • A61Q 19/08 - Anti-ageing preparations

16.

POLYLACTIDE RESIN COMPOSITION EXCELLENT IN CRYSTALLINITY DEGREE, AND METHOD FOR PREPARING THE SAME

      
Document Number 03220818
Status Pending
Filing Date 2023-02-27
Open to Public Date 2023-09-28
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • An, Yujin
  • Cho, Jeong Hun
  • Sung, Minchang
  • Oh, Wan Kyu

Abstract

The present disclosure relates to a polylactide resin composition prepared by combining specific nucleating agents and heat-treating them, which is characterized by having an excellent crystallinity degree.

IPC Classes  ?

  • C08K 5/00 - Use of organic ingredients
  • C08K 5/11 - Esters; Ether-esters of acyclic polycarboxylic acids
  • C08K 5/3432 - Six-membered rings
  • C08L 67/04 - Polyesters derived from hydroxy carboxylic acids, e.g. lactones

17.

POLYLACTIDE RESIN COMPOSITION EXCELLENT IN CRYSTALLINITY DEGREE, AND METHOD FOR PREPARING THE SAME

      
Document Number 03221739
Status Pending
Filing Date 2023-02-27
Open to Public Date 2023-09-28
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Cho, Jeong Hun
  • An, Yujin
  • Sung, Minchang
  • Oh, Wan Kyu

Abstract

The present disclosure relates to a polylactide resin composition that is used in combination with a specific nucleating agent, which is excellent in crystallinity degree and excellent in dispersibility between components and thus, also is excellent in transparency. Accordingly, it is possible to maintain the properties inherent in the polylactide resin according to the present disclosure while having excellent processability.

IPC Classes  ?

  • C08L 67/04 - Polyesters derived from hydroxy carboxylic acids, e.g. lactones
  • C08K 5/103 - Esters; Ether-esters of monocarboxylic acids with polyalcohols
  • C08K 5/3462 - Six-membered rings

18.

POLYLACTIDE RESIN COMPOSITION, AND METHOD FOR PREPARING THE SAME

      
Document Number 03229025
Status Pending
Filing Date 2023-03-15
Open to Public Date 2023-09-28
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Choe, Yeonji
  • Lee, Jeongkyu
  • Cho, Jeong Hun
  • An, Yujin
  • Oh, Sung Joon
  • Oh, Wan Kyu

Abstract

The present disclosure relates to a polylactide resin composition used in combination with a specific nucleating agent, which can relatively increase only the mobility of high molecular weight of the polylactide resin to improve the crystallinity degree, and at the same time, makes an amorphous region of the polylactide resin have a low glass transition temperature, thereby lowering the glass transition temperature of the polylactide resin composition, and simultaneously improving the crystallinity degree thereof.

IPC Classes  ?

  • C08L 67/04 - Polyesters derived from hydroxy carboxylic acids, e.g. lactones
  • C08K 5/101 - Esters; Ether-esters of monocarboxylic acids
  • C08K 5/3462 - Six-membered rings

19.

POLYLACTIDE RESIN COMPOSITION EXCELLENT IN CYSTALLIZATION HALF-LIFE, AND METHOD FOR PREPARING THE SAME

      
Document Number 03220807
Status Pending
Filing Date 2023-02-27
Open to Public Date 2023-09-28
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Cho, Jeong Hun
  • Lee, Jeongkyu
  • An, Yujin
  • Choe, Yeonji
  • Oh, Sung Joon
  • Oh, Wan Kyu

Abstract

The present disclosure relates to a polylactide resin composition that is used in combination with a specific nucleating agent, which is excellent in crystallization half-life and crystallinity degree, and thus, can maintain the properties inherent in the polylactide resin according to the present disclosure while having excellent processability.

IPC Classes  ?

  • C08L 67/04 - Polyesters derived from hydroxy carboxylic acids, e.g. lactones
  • C08K 5/00 - Use of organic ingredients
  • C08K 5/11 - Esters; Ether-esters of acyclic polycarboxylic acids
  • C08K 5/3432 - Six-membered rings

20.

POSITIVE ELECTRODE ACTIVE MATERIAL FOR LITHIUM SECONDARY BATTERY AND METHOD FOR PREPARING THE SAME

      
Document Number 03239473
Status Pending
Filing Date 2022-12-22
Open to Public Date 2023-06-29
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Eom, Jun Ho
  • Han, Song Yi
  • Lim, Chae Jin
  • Kim, Ji Hye
  • Lee, Jun Won
  • Kwak, No Woo

Abstract

The present invention relates to a positive electrode active material for a lithium secondary battery and a method for preparing the positive electrode active material.

IPC Classes  ?

  • C01G 53/00 - Compounds of nickel
  • H01M 4/505 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese of mixed oxides or hydroxides containing manganese for inserting or intercalating light metals, e.g. LiMn2O4 or LiMn2OxFy
  • H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
  • H01M 10/052 - Li-accumulators
  • H01M 4/02 - Electrodes composed of, or comprising, active material
  • H01M 4/36 - Selection of substances as active materials, active masses, active liquids
  • H01M 4/62 - Selection of inactive substances as ingredients for active masses, e.g. binders, fillers

21.

POSITIVE ELECTRODE ACTIVE MATERIAL AND METHOD FOR PRODUCING THE SAME

      
Document Number 03238308
Status Pending
Filing Date 2022-12-02
Open to Public Date 2023-06-08
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Mok, Duck Gyun
  • Lee, Hyuck
  • Son, Min Hee

Abstract

The present invention relates to a method for producing a positive electrode active material which can minimize the surface degradation of a positive electrode active material which occurs i n a washi ng process, effectively control residual lithium, and form a uniform coating layer on the surface of the positive electrode active material, and a positive electrode active material produced by the method, the method including the steps of: (A) preparing a lithium transition metal oxide; ( B) mixing the lithium transition metal oxide and a first washing solution to first wash and then first filter the lithium transition metal oxide; (C) simultaneously second washing and second filtering the lithium transition metal oxide through step ( B) using a filter device capable of washing and filtering simultaneously with a second washing solution; and ( D) drying the lithium transition metal oxide through step ( C) , then mixing a coating element-containing raw material with the dried lithium transition metal oxide and heat-treating the mixture to form a coating layer, wherein the coating element containing raw material includes a boron- containing raw material and at least one lithium - containing raw material selected from among Li OH, Li2CO3, and Li2O.

IPC Classes  ?

  • C01G 53/00 - Compounds of nickel
  • H01M 4/505 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese of mixed oxides or hydroxides containing manganese for inserting or intercalating light metals, e.g. LiMn2O4 or LiMn2OxFy
  • H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
  • H01M 10/052 - Li-accumulators
  • H01M 4/36 - Selection of substances as active materials, active masses, active liquids
  • H01M 4/62 - Selection of inactive substances as ingredients for active masses, e.g. binders, fillers

22.

METHOD OF PREPARING POSITIVE ELECTRODE ACTIVE MATERIAL FOR LITHIUM SECONDARY BATTERY, POSITIVE ELECTRODE ACTIVE MATERIAL FOR LITHIUM SECONDARY BATTERY, AND POSITIVE ELECTRODE FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY WHICH INCLUDE THE SAME

      
Document Number 03207888
Status Pending
Filing Date 2022-11-24
Open to Public Date 2023-06-01
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • You, Min Kyu
  • Shin, Sun Sik
  • Jin, Joo Hong
  • Lee, June Woo
  • Shin, Ji A
  • Park, Min Joo

Abstract

The present invention relates to a method of preparing a positive electrode active material having a high ratio of charge and discharge capacity at a charge end voltage of 4.1 V to 4.175 V to charge and discharge capacity at a charge end voltage of 4.2 V to 4.275 V and an excellent initial charge and discharge capacity.

IPC Classes  ?

  • C01G 53/00 - Compounds of nickel
  • H01M 4/505 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese of mixed oxides or hydroxides containing manganese for inserting or intercalating light metals, e.g. LiMn2O4 or LiMn2OxFy
  • H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
  • H01M 10/052 - Li-accumulators

23.

COMPOSITE FILLER, AND PRODUCT USING THE SAME

      
Document Number 03203845
Status Pending
Filing Date 2022-10-31
Open to Public Date 2023-05-04
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Kim, Yunseop
  • Kim, Lucia
  • Kim, Jee Seon

Abstract

The present disclosure relates to a composite filler comprising: porous inorganic particles including a sintered body of calcium-based particles and pores distributed in the sintered body; and a biodegradable carrier, and a product including the same.

IPC Classes  ?

  • A61L 27/46 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with phosphorus-containing inorganic fillers
  • A61L 27/12 - Phosphorus-containing materials, e.g. apatite
  • A61L 27/20 - Polysaccharides
  • A61L 27/56 - Porous or cellular materials
  • A61L 27/58 - Materials at least partially resorbable by the body

24.

METHOD FOR SYNTHESIZING CARBON NANOTUBES

      
Document Number 03232423
Status Pending
Filing Date 2022-10-19
Open to Public Date 2023-04-27
Owner
  • LG CHEM, LTD. (Republic of Korea)
  • TEKNA PLASMA SYSTEMS INC. (Canada)
Inventor
  • Kim, Dong Sik
  • Guo, Jiayin
  • Kim, Tae Hoon
  • Lee, Hyung Jin
  • Min, Geun Gi
  • Song, Doo Hoon
  • Kang, Soo Hee
  • Kim, Ye Byeol
  • Kim, Byoung Jin
  • Lee, Sung Hyun

Abstract

The present invention relates to a method for synthesizing carbon nanotubes by using a nanoparticle catalyst prepared by condensation after vaporization of catalytic raw material using plasma. When the manufacturing method of the present invention is used, the synthesized carbon nanotubes may have high crystallinity, and mass synthesis may be facilitated.

IPC Classes  ?

  • C01B 32/162 - Preparation characterised by catalysts
  • B01J 19/08 - Processes employing the direct application of electric or wave energy, or particle radiation; Apparatus therefor
  • B82Y 40/00 - Manufacture or treatment of nanostructures

25.

APPARATUS FOR SYNTHESIZING CARBON NANOTUBES

      
Document Number 03232446
Status Pending
Filing Date 2022-10-19
Open to Public Date 2023-04-27
Owner
  • LG CHEM, LTD. (Republic of Korea)
  • TEKNA PLASMA SYSTEMS INC. (Canada)
Inventor
  • Kim, Dong Sik
  • Guo, Jiayin
  • Kim, Tae Hoon
  • Lee, Hyung Jin
  • Min, Geun Gi
  • Song, Doo Hoon
  • Kang, Soo Hee
  • Kim, Ye Byeol
  • Kim, Byoung Jin
  • Lee, Sung Hyun

Abstract

The present invention relates to a carbon nanotube manufacturing apparatus including a plasma device and a CVD reactor which are connected in series, in which a nanoparticle catalyst in an aerosol state prepared in the plasma device is transferred into the CVD reactor to synthesize carbon nanotubes, and thus carbon nanotubes having excellent physical properties can be continuously synthesized.

IPC Classes  ?

  • C01B 32/164 - Preparation involving continuous processes
  • C01B 32/162 - Preparation characterised by catalysts
  • B01J 13/00 - Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
  • B01J 19/08 - Processes employing the direct application of electric or wave energy, or particle radiation; Apparatus therefor
  • B01J 19/24 - Stationary reactors without moving elements inside

26.

POSITIVE ELECTRODE ACTIVE MATERIAL FOR LITHIUM SECONDARY BATTERY, AND METHOD OF PREPARING THE SAME

      
Document Number 03217171
Status Pending
Filing Date 2022-10-14
Open to Public Date 2023-04-20
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Do, Joong Yeop
  • Shin, Sun Sik
  • Shin, Ho Suk

Abstract

The present invention relates to a cathode active material for a lithium secondary battery and a method for manufacturing the cathode active material.

IPC Classes  ?

  • H01M 4/36 - Selection of substances as active materials, active masses, active liquids
  • H01M 4/505 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese of mixed oxides or hydroxides containing manganese for inserting or intercalating light metals, e.g. LiMn2O4 or LiMn2OxFy
  • H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
  • H01M 10/052 - Li-accumulators
  • C01G 53/00 - Compounds of nickel
  • H01M 4/02 - Electrodes composed of, or comprising, active material
  • H01M 4/62 - Selection of inactive substances as ingredients for active masses, e.g. binders, fillers

27.

METHOD FOR PREPARING INTERMEDIATE FOR SYNTHESIS OF XANTHINE OXIDASE INHIBITOR

      
Document Number 03221122
Status Pending
Filing Date 2022-07-01
Open to Public Date 2023-01-05
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Lee, Seok Ju
  • Park, Ah Byeol
  • Lee, Ju Yeol
  • Kim, Ki Dae
  • Jeong, Hui Rak

Abstract

The present invention relates to a method for preparing an intermediate for synthesis of a xanthine oxidase inhibitor and, more specifically, to a method for preparing compounds of chemical formulas 2 and 4 by using low-priced starting materials and ligands and employing chelating extraction and purification techniques.

IPC Classes  ?

  • C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
  • C07D 209/04 - Indoles; Hydrogenated indoles
  • C07D 209/14 - Radicals substituted by nitrogen atoms, not forming part of a nitro radical
  • C07D 209/42 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

28.

METHOD FOR PREPARING XANTHINE OXIDASE INHIBITOR

      
Document Number 03221525
Status Pending
Filing Date 2022-07-01
Open to Public Date 2023-01-05
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Lee, Seok Ju
  • Jeong, Hui Rak
  • Ham, Jin Ok
  • Shin, Doo Sup

Abstract

The present invention relates to a method for preparing a xanthine oxidase inhibitor and, more specifically, to a method for preparing a compound of chemical formula 2 by using ester hydrolysis and a recrystallization method.

IPC Classes  ?

  • C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond

29.

ORAL FORMULATION CONTAINING 1-(3-CYANO-1-ISOPROPYL-INDOL-5-YL)PYRAZOLE-4-CARBOXYLIC ACID

      
Document Number 03221172
Status Pending
Filing Date 2022-06-17
Open to Public Date 2022-12-22
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Yoo, Seok Cheol
  • Jang, Joomyung
  • Kim, Ree Sun
  • Seo, Jin A

Abstract

The present invention relates to an oral formulation that contains an API selected from 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid or a pharmaceutically acceptable salt thereof, and does not contain pH adjusting agents as excipients. The oral formulation according to the present invention does not contain pH adjusting agents, and thus has the advantages of having increased productivity and convenience of dosage, as well as a high dissolution rate, despite having a high API content.

IPC Classes  ?

  • A61K 9/20 - Pills, lozenges or tablets
  • A61K 31/4152 - 1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone

30.

PHARMACEUTICAL COMPOSITION COMPRISING 1-(3-CYANO-1-ISOPROPYL-INDOL-5-YL)PYRAZOLE-4-CARBOXYLIC ACID

      
Document Number 03221017
Status Pending
Filing Date 2022-06-15
Open to Public Date 2022-12-22
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Lee, Jieun
  • Gwak, Heemin
  • Shin, Seong Hye
  • Min, Ji Young
  • Kim, Min Hee
  • Kim, Junyu
  • Seo, Jung Youn
  • Mune, June Sik

Abstract

The present invention relates to a pharmaceutical composition comprising 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazol-4-carboxylic acid or a pharmaceutically acceptable salt thereof, and a method of treating or preventing a hyperuricemia-related disease using the same, and the pharmaceutical composition of the present invention may effectively reduce the blood uric acid concentration in a patient with a hyperuricemia-related disease.

IPC Classes  ?

  • A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
  • A61P 19/06 - Antigout agents, e.g. antihyperuricemic or uricosuric agents

31.

PHARMACEUTICAL COMPOSITION COMPRISING 1-(3-CYANO-1-ISOPROPYL-INDOL-5-YL)PYRAZOLE-4-CARBOXYLIC ACID

      
Document Number 03221533
Status Pending
Filing Date 2022-06-15
Open to Public Date 2022-12-22
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Lee, Jieun
  • Gwak, Heemin
  • Shin, Seong Hye
  • Min, Ji Young
  • Kim, Min Hee
  • Kim, Junyu
  • Seo, Jung Youn
  • Mune, June Sik

Abstract

The present invention relates to a pharmaceutical composition comprising 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazol-4-carboxylic acid or a pharmaceutically acceptable salt thereof, and a method of treating or preventing a hyperuricemia-related disease using the same, and the pharmaceutical composition of the present invention may effectively reduce the blood uric acid concentration in a patient with a hyperuricemia-related disease.

IPC Classes  ?

  • A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
  • A61P 19/06 - Antigout agents, e.g. antihyperuricemic or uricosuric agents

32.

METHOD FOR PRERARING ISOPROPYL ALCOHOL

      
Document Number 03164678
Status Pending
Filing Date 2021-12-05
Open to Public Date 2022-12-08
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Park, Sa Eun
  • Lee, Sung Kyu
  • Kim, Tae Woo

Abstract

Provided is a method of preparing isopropyl alcohol. The method of preparing isopropyl alcohol allows separation of a reaction product stream formed by reacting a propylene monomer and water in a reactor into an unreacted propylene monomer and isopropyl alcohol with high purity using an absorption column, a gas purification column, and an inert gas removal column.

IPC Classes  ?

  • C07C 29/76 - Separation; Purification; Stabilisation; Use of additives by physical treatment
  • C07C 29/04 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by addition of hydroxy groups to unsaturated carbon-to-carbon bonds, e.g. with the aid of H2O2 by hydration of carbon-to-carbon double bonds

33.

METHOD FOR PRERARING ISOPROPYL ALCOHOL

      
Document Number 03164721
Status Pending
Filing Date 2021-12-05
Open to Public Date 2022-12-08
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Park, Sa Eun
  • Choi, Byung Woo
  • Lee, Sung Kyu
  • Kim, Sung Kyun
  • Kim, Tae Woo

Abstract

Provided is a method of preparing isopropyl alcohol. In the method of preparing isopropyl alcohol, a propylene monomer and water are reacted in a reactor to produce a reaction product including isopropyl alcohol, and the reaction product stream may be separated into an unreacted propylene monomer and isopropyl alcohol with high purity using an absorption column, a first gas purification column, a second gas purification column, and an inert gas removal column.

IPC Classes  ?

  • C07C 29/76 - Separation; Purification; Stabilisation; Use of additives by physical treatment
  • C07C 29/04 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by addition of hydroxy groups to unsaturated carbon-to-carbon bonds, e.g. with the aid of H2O2 by hydration of carbon-to-carbon double bonds

34.

METHOD OF PREPARING ISOPROPYL ALCOHOL

      
Document Number 03178359
Status Pending
Filing Date 2022-04-29
Open to Public Date 2022-11-10
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Park, Sa Eun
  • Kim, Tae Woo
  • Choi, Byung Woo
  • Lee, Sung Kyu

Abstract

Provided is a method of preparing isopropyl alcohol including: supplying a feed stream including a propylene monomer and water to a reaction unit and performing a reaction to produce a reaction product including isopropyl alcohol, the propylene monomer, and the water; supplying a first discharge stream including a gaseous reaction product and a second discharge stream including a liquid reaction product which are discharged from the reaction unit to a stripper, respectively; and in the stripper, circulating an upper discharge stream including the propylene monomer to the reaction unit and supplying a lower discharge stream including water and isopropyl alcohol to an isopropyl alcohol purification unit, wherein the first discharge stream is condensed by a first heat exchanger and supplied as a liquid phase to the striSpper.

IPC Classes  ?

  • C07C 29/76 - Separation; Purification; Stabilisation; Use of additives by physical treatment
  • C07C 29/04 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by addition of hydroxy groups to unsaturated carbon-to-carbon bonds, e.g. with the aid of H2O2 by hydration of carbon-to-carbon double bonds

35.

CRYSTALLINE FORM V OF MELANOCORTIN RECEPTOR AGONIST COMPOUND, AND METHOD FOR PREPARING SAME

      
Document Number 03217168
Status Pending
Filing Date 2022-05-06
Open to Public Date 2022-11-10
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Ham, Jin Ok
  • Lee, Ho Yeon
  • Lee, Sang Dae
  • Kim, Ji Yoon
  • Park, Jong Won
  • Kim, Sung Won
  • Chun, Seul Ah

Abstract

The present invention relates to crystalline form V of a compound represented by chemical formula 1, a method for preparing same, and a pharmaceutical composition comprising same. Crystalline form V of the compound represented by chemical formula 1 according to the present invention may be characterized by an XRD pattern, a DSC profile, and/or a TGA profile.

IPC Classes  ?

  • C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
  • A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
  • A61P 3/04 - Anorexiants; Antiobesity agents
  • A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
  • A61P 15/10 - Drugs for genital or sexual disorders; Contraceptives for impotence
  • A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

36.

SULFATE CRYSTALS OF MELANOCORTIN RECEPTOR AGONIST COMPOUND AND METHOD OF PRODUCING SAME

      
Document Number 03217198
Status Pending
Filing Date 2022-05-06
Open to Public Date 2022-11-10
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Kim, Ji Yoon
  • Chun, Seul Ah
  • Kim, Sung Won

Abstract

The present invention relates to a sulfate crystal form of a compound represented by formula 1, a method of producing same, and a pharmaceutical composition comprising same. The sulfate crystal form of the compound represented by formula 1 of the present invention may be characterized by an XRPD pattern, a DSC profile, and/or a TGA profile.

IPC Classes  ?

  • C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
  • A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
  • A61P 3/04 - Anorexiants; Antiobesity agents
  • A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
  • A61P 15/10 - Drugs for genital or sexual disorders; Contraceptives for impotence
  • A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

37.

CRYSTAL FORM VII OF MELANOCORTIN RECEPTOR AGONIST COMPOUND AND METHOD FOR PREPARING SAME

      
Document Number 03217201
Status Pending
Filing Date 2022-05-06
Open to Public Date 2022-11-10
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Lee, Ho Yeon
  • Ham, Jin Ok
  • Lee, Sang Dae
  • Kim, Ji Yoon
  • Park, Jong Won
  • Kim, Sung Won
  • Chun, Seul Ah

Abstract

The present invention relates to a crystal form VII of a compound represented by chemical formula 1, a method for preparing same, and a pharmaceutical composition comprising same. The crystal form VII of the compound represented by chemical formula 1, according to the present invention, can be characterized by an XRD pattern, a DSC profile, and/or a TGA profile.

IPC Classes  ?

  • C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
  • A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
  • A61P 3/04 - Anorexiants; Antiobesity agents
  • A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
  • A61P 15/10 - Drugs for genital or sexual disorders; Contraceptives for impotence
  • A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

38.

CRYSTAL FORM IV OF ORGANIC ACID SALTS OF MELANOCORTIN RECEPTOR AGONIST COMPOUND, AND PREPARATION METHOD THEREOF

      
Document Number 03217468
Status Pending
Filing Date 2022-05-06
Open to Public Date 2022-11-10
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Kim, Ji Yoon
  • Chun, Seul Ah
  • Kim, Sung Won

Abstract

The present invention relates to a crystal form IV of organic acid salts of a compound represented by chemical formula 1, a preparation method thereof, and a pharmaceutical composition comprising same. The crystal form IV of organic acid salts of the compound represented by chemical formula 1 of the present invention may be characterized by an XRPD pattern, a DSC profile and/or a TGA profile.

IPC Classes  ?

  • C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
  • A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
  • A61P 3/04 - Anorexiants; Antiobesity agents
  • A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
  • A61P 15/10 - Drugs for genital or sexual disorders; Contraceptives for impotence
  • A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

39.

ORAL FORMULATION CONTAINING 1-(3-CYANO-1-ISOPROPYL-INDOL-5-YL) PYRAZOLE-4-CARBOXYLIC ACID

      
Document Number 03213929
Status Pending
Filing Date 2022-04-15
Open to Public Date 2022-10-20
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Yoo, Seok Cheol
  • Jang, Joomyung
  • Seo, Jin A
  • Lim, Dohyung

Abstract

The present invention relates to a composite formulation for oral administration comprising an active pharmaceutical ingredient (API) selected from 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazol-4-carboxylic acid or a pharmaceutically acceptable salt thereof, wherein the API has a particle size of granules corresponding to 90% of the maximum particle size in the cumulative particle size distribution (D(0.9)) of 80 ?m or more and 300 ?m or less.The composite formulation for oral administration according to the present invention has a low friability and an increased dissolution rate even if a high content of API is included, by regulating the particle size of the API to a certain range.

IPC Classes  ?

  • A61K 9/20 - Pills, lozenges or tablets
  • A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings

40.

GUCY2C BINDING POLYPEPTIDE AND USES THEREOF

      
Document Number 03211331
Status Pending
Filing Date 2022-04-07
Open to Public Date 2022-10-13
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Kim, Youngkyun
  • Shin, Jung Youn
  • Ko, Yeongrim
  • Yang, Soyeon
  • Hong, Beom Ju
  • Choi, Eunhye
  • Lee, Nakyoung

Abstract

The present disclosure pertains to a GUCY2C-binding polypeptide and uses thereof and, specifically, to a GUCY2C-binding polypeptide, a fusion protein including same, a chimeric antigen receptor, an immune cell expressing the chimeric antigen receptor, and a use thereof for treatment and/or diagnosis of cancer.

IPC Classes  ?

  • A61K 38/00 - Medicinal preparations containing peptides
  • A61P 35/00 - Antineoplastic agents
  • C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
  • C12N 15/62 - DNA sequences coding for fusion proteins
  • C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
  • G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer
  • G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

41.

USE OF MELANOCORTIN-4 RECEPTOR AGONIST

      
Document Number 03203998
Status Pending
Filing Date 2022-01-20
Open to Public Date 2022-07-28
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Park, Hee Dong
  • Yeo, Su Jin
  • Ahn, Hye Won

Abstract

The present invention relates to uses of a compound of chemical formula 1 or a pharmaceutically acceptable salt thereof for the purpose of preventing or treating rare genetic obesity diseases, particularly rare genetic obesity diseases associated with a damaged melanocortin-4 receptor (MC4R) pathway.

IPC Classes  ?

  • A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
  • A61P 3/04 - Anorexiants; Antiobesity agents

42.

CROSSLINKED HYALURONIC ACID HYDROGEL CROSSLINKED USING CROSSLINKER AND POLYOL, AND FILLER COMPRISING SAME

      
Document Number 03201990
Status Pending
Filing Date 2022-01-07
Open to Public Date 2022-07-14
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Jung, Hyun Tae
  • Lee, Chung
  • So, Jineon

Abstract

The present invention provides a crosslinked hyaluronic acid hydrogel in which a crosslinking agent and a polyol are used to reduce toxicity during crosslinking, and thereby enhance safety while increasing persistence in the body; and a filler composition including the crosslinked hyaluronic acid hydrogel.

IPC Classes  ?

43.

POLYPEPTIDE SPECIFIC FOR MUCIN 1 AND USE THEREOF

      
Document Number 03203067
Status Pending
Filing Date 2021-12-24
Open to Public Date 2022-06-30
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Lee, Ji Hyun
  • Lee, Hae Youn
  • Choi, Yoon Aa
  • Yi, Dae Gwan
  • Choi, Jungwon
  • Park, Areum
  • Jung, Saem
  • Song, Eu Rim
  • Na, Kyubong
  • Park, Min Jeong
  • Jeun, Eun Ji
  • Choe, Kyuhong
  • Yi, Hyoju
  • Yang, Hee Jung
  • Jang, Sung Woong

Abstract

The present invention relates to a polypeptide binding to mucin 1, an isolated polynucleotide encoding same, a vector carrying the polynucleotide, and a cell including the vector. In addition, the present invention relates to a chimeric antigen receptor including the polypeptide binding to mucin 1, an isolated polynucleotide encoding the chimeric antigen receptor, a vector carrying the polynucleotide, an immune cell expressing the chimeric antigen receptor, a composition comprising same for treatment of cancer, and a method for treatment of cancer.

IPC Classes  ?

  • C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
  • A61K 35/17 - Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
  • C07K 14/705 - Receptors; Cell surface antigens; Cell surface determinants

44.

USE AS SELECTIVE AGONIST OF MALANOCORTIN-4 RECEPTOR

      
Document Number 03202315
Status Pending
Filing Date 2021-12-21
Open to Public Date 2022-06-30
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Park, Hee Dong
  • Yeo, Su Jin
  • Park, Hyun Seo
  • Park, Jin Sook
  • Ahn, Hye Won

Abstract

The present invention relates to use of a compound of chemical formula 1 or a pharmaceutically acceptable salt thereof as a selective agonist of the melanocortin-4-receptor (MC4R).

IPC Classes  ?

  • A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
  • A61P 3/04 - Anorexiants; Antiobesity agents
  • A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
  • A61P 15/10 - Drugs for genital or sexual disorders; Contraceptives for impotence

45.

DIP-FORMED ARTICLE COMPRISING A LAYER DERIVED FROM LATEX COMPOSITION FOR DIP-FORMING

      
Document Number 03162452
Status Pending
Filing Date 2021-12-09
Open to Public Date 2022-06-16
Owner
  • LG CHEM, LTD. (Republic of Korea)
  • MIDORI ANZEN CO., LTD. (Japan)
Inventor
  • Kwon, Won Sang
  • Yeu, Seung Uk
  • Han, Jung Su
  • Kim, Jung Eun
  • Jang, Myung Su
  • Enomoto, Norihide
  • Hoshino, Sayaka
  • Satake, Shoya
  • Takeuchi, Yamato

Abstract

The present invention provides a dip-formed article that has an excellent stress retention rate and is easily stretched and soft. The present invention provides a dip-formed article comprising a layer derived from a latex composition for dip-forming, wherein the latex composition for dip-forming contains a carboxylic acid-modified nitrile-based copolymer latex, the carboxylic acid-modified nitrile-based copolymer latex contains a carboxylic acid-modified nitrile-based copolymer, and the dip-formed article has an elongation of more than 650% and satisfies the following Expressions 1 and 2,[Expression 1]k1? + k2? + k3? ? 9.3 N/mm(1)[Expression 2]0.55 ? k1?/(k1? + k2? + k3?)(2)wherein k1? is a value obtained by dividing an equilibrium coefficient k1 by a thickness of a test piece, and k2? and k3? are values obtained by dividing viscous coefficients k2 and k3 by the thickness of the test piece, respectively.

IPC Classes  ?

46.

STABLE ORAL FORMULATION CONTAINING 1-(3-CYANO-1-ISOPROPYL-INDOL-5-YL) PYRAZOLE-4-CARBOXYLIC ACID

      
Document Number 03197405
Status Pending
Filing Date 2021-11-30
Open to Public Date 2022-06-09
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Yoo, Seok Cheol
  • Lee, Sun
  • Yun, Duck Il
  • Park, Junghong
  • Sun, Hyun Ji

Abstract

The present invention relates to a stable oral formulation comprising 1-(3-cyano-1-isopropyl-indol-5-yl) pyrazol-4-carboxylic acid or a pharmaceutically acceptable salt thereof as an API. The stable oral formulation according to the present invention has the characteristics of maintaining stability even if it does not comprise a stabilizer as an excipient, and does not comprise a stabilizer but has increased API content, and thus the convenience of administration can be increased.

IPC Classes  ?

  • A61K 9/20 - Pills, lozenges or tablets
  • A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
  • A61P 19/06 - Antigout agents, e.g. antihyperuricemic or uricosuric agents

47.

ORAL FORMULATION COMPRISING 1-(3-CYANO-1-ISOPROPYL-INDOLE-5-YL)PYRAZOLE-4-CARBOXYLIC ACID AND METHOD FOR PREPARING SAME

      
Document Number 03195598
Status Pending
Filing Date 2021-11-30
Open to Public Date 2022-06-09
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Yoo, Seok Cheol
  • Jang, Joomyung
  • Kim, Ree Sun
  • Seo, Jin A

Abstract

The present invention relates to an oral formulation comprising an API selected from 1-(3-cyano-1-isopropylindol-5-yl)pyrazol-4-carboxylic acid or a pharmaceutically acceptable salt thereof in high content. Since the oral formulation according to the present invention has a high content and excellent physical properties by comprising a glidant in excipients, economic efficiency and the convenience of administration can be increased.

IPC Classes  ?

  • A61K 9/20 - Pills, lozenges or tablets
  • A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings

48.

METHOD FOR PREPARING CRYSTALLINE PARTICLES OF 1-(3-CYANO-1-ISOPROPYL-INDOLE-5-YL)PYRAZOLE-4-CARBOXYLIC ACID, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

      
Document Number 03194595
Status Pending
Filing Date 2021-11-02
Open to Public Date 2022-05-12
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Lee, Seok Ju
  • Park, Ah Byeol
  • Jeong, Hui Rak
  • Ham, Jinok
  • Shin, Doosup

Abstract

The present invention relates to a pharmaceutical composition comprising crystalline particles comprising the compound of Formula 1 or a pharmaceutically acceptable salt thereof comprising the compound of Formula 2 below in an amount of 0.2 wt.% or less. The crystalline particles according to the present invention, have a size, shape and distribution that improve uniformity and flowability as well as being optimized for input into the preparation process of the finished drug product, thereby increasing the content uniformity in the preparation process of the finished product and minimizing breakage during compressing into tablets, and thus can be used as a raw material pharmaceutical product suitable for the preparation process of the finished drug product.?Representive figure?FIG. 1

IPC Classes  ?

  • A61K 9/20 - Pills, lozenges or tablets
  • A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
  • A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
  • A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
  • A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
  • A61P 9/12 - Antihypertensives
  • A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
  • A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
  • A61P 19/06 - Antigout agents, e.g. antihyperuricemic or uricosuric agents

49.

AMORPHOUS MELANOCORTIN-4 RECEPTOR AGONIST

      
Document Number 03195214
Status Pending
Filing Date 2021-10-29
Open to Public Date 2022-05-05
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Ham, Jin Ok
  • Lee, Ho Yeon
  • Kim, Ji Yoon
  • Kim, Sung Won
  • Chun, Seul Ah
  • Lee, Sang Dae
  • Park, Jong Won

Abstract

The present invention relates to an amorphous compound represented by formula 1, a method for preparing the same, and a pharmaceutical composition comprising the same. The amorphous compound represented by formula 1 of the present invention may be characterized by XRD patterns, DSC profiles, and/or TGA profiles.

IPC Classes  ?

  • C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
  • A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
  • A61P 3/04 - Anorexiants; Antiobesity agents
  • A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
  • A61P 15/10 - Drugs for genital or sexual disorders; Contraceptives for impotence

50.

CRYSTALLINE FORM IV OF MELANOCORTIN RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD THEREFOR

      
Document Number 03195328
Status Pending
Filing Date 2021-10-29
Open to Public Date 2022-05-05
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Ham, Jin Ok
  • Lee, Ho Yeon
  • Kim, Ji Yoon
  • Kim, Sung Won
  • Chun, Seul Ah
  • Lee, Sang Dae
  • Park, Jong Won

Abstract

The present invention relates to a crystalline form IV represented by formula 1, a method for preparing the same, and a pharmaceutical composition comprising the same. The crystalline form IV represented by formula 1 of the present invention may be characterized by XRD patterns, DSC profiles, and/or TGA profiles.

IPC Classes  ?

  • C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
  • A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
  • A61P 3/04 - Anorexiants; Antiobesity agents
  • A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
  • A61P 15/10 - Drugs for genital or sexual disorders; Contraceptives for impotence

51.

CRYSTALLINE FORM II OF MELANOCORTIN RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD THEREFOR

      
Document Number 03195432
Status Pending
Filing Date 2021-10-29
Open to Public Date 2022-05-05
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Ham, Jin Ok
  • Lee, Ho Yeon
  • Kim, Ji Yoon
  • Kim, Sung Won
  • Chun, Seul Ah
  • Lee, Sang Dae
  • Park, Jong Won

Abstract

The present invention relates to a crystalline form II represented by formula 1, a method for preparing the same, and a pharmaceutical composition comprising the same. The crystalline form II represented by formula 1 of the present invention may be characterized by XRD patterns, DSC profiles, and/or TGA profiles.

IPC Classes  ?

  • C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
  • A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
  • A61P 3/04 - Anorexiants; Antiobesity agents
  • A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
  • A61P 15/10 - Drugs for genital or sexual disorders; Contraceptives for impotence

52.

CRYSTALLINE FORM I OF MELANOCORTIN RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD THEREFOR

      
Document Number 03195298
Status Pending
Filing Date 2021-10-29
Open to Public Date 2022-05-05
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Ham, Jin Ok
  • Lee, Ho Yeon
  • Kim, Ji Yoon
  • Kim, Sung Won
  • Chun, Seul Ah
  • Lee, Sang Dae
  • Park, Jong Won

Abstract

The present invention relates to a crystalline form I represented by formula 1, a method for preparing the same, and a pharmaceutical composition comprising the same. The crystalline form I represented by formula 1 of the present invention may be characterized by XRD patterns, DSC profiles, and/or TGA profiles.

IPC Classes  ?

  • C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
  • A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
  • A61P 3/04 - Anorexiants; Antiobesity agents
  • A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
  • A61P 15/10 - Drugs for genital or sexual disorders; Contraceptives for impotence

53.

CRYSTALLINE FORM III OF MELANOCORTIN RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD THEREFOR

      
Document Number 03195304
Status Pending
Filing Date 2021-10-29
Open to Public Date 2022-05-05
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Ham, Jin Ok
  • Lee, Ho Yeon
  • Kim, Ji Yoon
  • Kim, Sung Won
  • Chun, Seul Ah
  • Lee, Sang Dae
  • Park, Jong Won

Abstract

The present invention relates to a crystalline form III represented by formula 1, a method for preparing the same, and a pharmaceutical composition comprising the same. The crystalline form III represented by formula 1 of the present invention may be characterized by XRD patterns, DSC profiles, and/or TGA profiles.

IPC Classes  ?

  • C07D 207/16 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
  • A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
  • A61P 3/04 - Anorexiants; Antiobesity agents
  • A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
  • A61P 15/10 - Drugs for genital or sexual disorders; Contraceptives for impotence
  • C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

54.

USE OF SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST

      
Document Number 03192701
Status Pending
Filing Date 2021-09-27
Open to Public Date 2022-03-31
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Kim, Ki Chan
  • Kim, Tae Hun

Abstract

The present invention relates to use of a compound of chemical formula 1 or a pharmaceutically acceptable salt thereof for the prevention or treatment of atopic dermatitis.

IPC Classes  ?

  • A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
  • A61P 17/00 - Drugs for dermatological disorders

55.

NOVEL BIARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR, AND USE THEREOF

      
Document Number 03189681
Status Pending
Filing Date 2021-09-03
Open to Public Date 2022-03-10
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Yoon, Seung Hyun
  • Joo, Hyun Woo
  • Seo, Bo Kyung
  • Lee, Eun Jin
  • Jung, Jin Young
  • Yoon, Su Young
  • Cho, Woo Young

Abstract

The present invention relates to a biaryl derivative compound, which exhibits the activity of a diacylglycerol acyltransferase 2 (DGAT2) inhibitor and is represented by chemical formula (1), a pharmaceutical composition comprising same as an active ingredient, and a use thereof.

IPC Classes  ?

  • C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
  • A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
  • A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
  • A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
  • A61P 3/04 - Anorexiants; Antiobesity agents
  • A61P 3/06 - Antihyperlipidemics
  • A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
  • A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
  • C07D 241/16 - Halogen atoms; Nitro radicals

56.

METHOD FOR PREPARING SUPPORTED METALLOCENE CATALYST, SUPPORTED METALLOCENE CATALYST, AND METHOD FOR PREPARING POLYOLEFIN USING THE SAME

      
Document Number 03172704
Status Pending
Filing Date 2021-08-05
Open to Public Date 2022-02-17
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Jeong, Cheolhwan
  • Lee, Seungmi
  • Lee, Jung Won
  • Kwon, Hyun Jee
  • Kwon, Yongwoo

Abstract

This invention relates to a method for preparing a supported metallocene catalyst, a supported metallocene catalyst and a method for preparing polyolefin using the same. According to this invention, a method for preparing a supported metallocene catalyst that not only has excellent olefin polymerization activity, but also enables preparation of polyolefin having a uniform powder morphology, a supported metallocene catalyst prepared by the method, and a method for preparing polyolefin using the supported metallocene catalyst are provided.

IPC Classes  ?

  • C08F 4/659 - Component covered by group containing a transition metal-carbon bond
  • C08F 4/02 - Carriers therefor
  • C08F 4/6592 - Component covered by group containing a transition metal-carbon bond containing at least one cyclopentadienyl ring, condensed or not, e.g. an indenyl or a fluorenyl ring

57.

USE OF CASPASE INHIBITOR FOR ALLEVIATING OR TREATING OSTEOARTHRITIS

      
Document Number 03185212
Status Pending
Filing Date 2021-08-04
Open to Public Date 2022-02-10
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Baek, Jae Uk
  • Park, Jung Gyu
  • Kim, Sung Won
  • Park, Hyun Seo
  • Choi, Sei Hyun
  • Jin, Myung Won
  • Lee, Min Kyoung

Abstract

The present invention relates to a use of a caspase inhibitor for alleviating or treating osteoarthritis.

IPC Classes  ?

  • A61K 38/05 - Dipeptides
  • A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
  • A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
  • A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
  • A61K 38/06 - Tripeptides
  • A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

58.

ANTI-LILRB1 ANTIBODY AND USES THEREOF

      
Document Number 03186256
Status Pending
Filing Date 2021-07-27
Open to Public Date 2022-02-03
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Choi, Yoon Aa
  • Kim, Han Byul
  • Kang, Shinyoung
  • Kim, Jung A
  • Kim, Heehang
  • Kim, Minsoon
  • Cho, Junhaeng

Abstract

The present invention relates to an anti-LILRB1 antibody having increased specificity for LILRB1, and to uses thereof. Specifically, an anti-LILRB1 antibody or an antigen-binding fragment thereof, and uses thereof in treating cancer are provided.

IPC Classes  ?

  • C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

59.

COMPOSITION FOR PREVENTING OR TREATING OSTEOARTHRITIS, COMPRISING MESENCHYMAL STEM CELL EXPRESSING TUMOR NECROSIS FACTOR-INDUCIBLE GENE 6

      
Document Number 03184920
Status Pending
Filing Date 2021-07-16
Open to Public Date 2022-01-20
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Ryu, Je Young
  • Nam, Seung Woo
  • Kim, Chang Young
  • Kim, Donghoon
  • Shin, Jung Youn

Abstract

The present application relates to a use for cartilage regeneration and/or use for osteoarthritis treatment of a mesenchymal stem cell expressing TSG-6 protein. The present application provides a composition for cartilage regeneration and a pharmaceutical compositionfor osteoarthritis treatment, comprising a mesenchymal stem cell expressing TSG-6 protein as an active ingredient. The composition for cartilage regeneration and/or the pharmaceutical composition for osteoarthritis treatment provided by the present application can increase collagen expression of cartilage cells, reduce inflammation, and restore the cartilage structure.

IPC Classes  ?

  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 35/28 - Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
  • A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
  • A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

60.

MULTIMERIC T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF

      
Document Number 03178427
Status Pending
Filing Date 2021-05-11
Open to Public Date 2021-11-18
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Lee, Ji Hyun
  • Ryu, Su Jeong

Abstract

The present disclosure provides T-cell modulatory multimeric polypeptides that comprise an immunomodulatory polypeptide and that comprise an epitope-presenting Wilms tumor peptide. A T-cell modulatory multimeric polypeptide is useful for modulating the activity of a T cell, and for modulating an immune response in an individual.

IPC Classes  ?

  • C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
  • C07K 14/55 - IL-2
  • C07K 14/74 - Major histocompatibility complex (MHC)

61.

GLP-1 RECEPTOR AGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND METHOD FOR PREPARING SAME

      
Document Number 03171173
Status Pending
Filing Date 2021-03-17
Open to Public Date 2021-09-23
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Kim, Young Kwan
  • Jo, Min Mi
  • Park, Jun

Abstract

The present invention relates to a novel compound of the general Formula I, wherein the compound is useful as an agent for treatment or prophylaxis of various metabolic diseases such as obesity or diabetes and hyperlipidemia, by means of excellent GLP-1 agonist activity and an excellent DMPK profile, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the compound, and a method for preparing the compound.

IPC Classes  ?

  • C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
  • A61K 31/4439 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
  • A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
  • C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
  • C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

62.

COMPOSITION COMPRISING ANTIGEN-PRESENTING CELL CO-EXPRESSING MHC AND TUMOR ANTIGEN, AND CANCER TREATMENT USING SAME

      
Document Number 03164306
Status Pending
Filing Date 2021-01-08
Open to Public Date 2021-07-15
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Sheen, Joon Ho
  • Kwon, Joon Cheol
  • Kim, Seunghae

Abstract

The present invention relates to a vaccine composition for preventing or treating cancer comprising antigen-presenting cells, on the cell surface of which a composite of major histocompatibility complex (MHC) and tumor antigen is overexpressed.

IPC Classes  ?

  • C12N 15/62 - DNA sequences coding for fusion proteins
  • C12N 5/0784 - Dendritic cells; Progenitors thereof
  • A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
  • A61K 39/00 - Medicinal preparations containing antigens or antibodies
  • A61P 35/00 - Antineoplastic agents
  • C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
  • C07K 14/74 - Major histocompatibility complex (MHC)

63.

NOVEL AMIDE DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR, AND USE THEREOF

      
Document Number 03161640
Status Pending
Filing Date 2020-12-22
Open to Public Date 2021-07-01
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Yoon, Seung Hyun
  • Joo, Hyun Woo
  • Seo, Bo Kyung
  • Lee, Eun Jin
  • Jung, Jin Young
  • Yoon, Su Young
  • Kwak, Young Shin
  • Cho, Woo Young
  • Jo, Min Mi

Abstract

The present invention relates to an amide derivative compound, which exhibits the activity of a diacylglycerol acyltransferase (DGAT) 2 inhibitor and is represented by chemical Formula (1)or a pharmaceutically acceptable salt or isomer thereof, a pharmaceutical composition comprising same as an active ingredient, and a use thereof.

IPC Classes  ?

  • C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
  • A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
  • A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
  • C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

64.

AMINO ARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR AND USE THEREOF

      
Document Number 03160366
Status Pending
Filing Date 2020-12-22
Open to Public Date 2021-07-01
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Yoon, Seung Hyun
  • Joo, Hyun Woo
  • Seo, Bo Kyung
  • Lee, Eun Jin
  • Jung, Jin Young
  • Yoon, Su Young
  • Cho, Woo Young

Abstract

A compound of formula (1) or a pharmaceutically acceptable salt or stereoisomer thereof,wherein A and D are each independently CH or N; B and E are each independently CH, C-halogen, C-haloalkyl or N; R1 is alkyl, cycloalkyl or haloalkyl; R2 is hydrogen, halogen or alkyl; R3 is -G-J; G is aryl, arylene, arylene-alkylene, heteroaryl or heteroarylene; wherein J is hydrogen, amino, aminocarbonyl, alkoxy-alkyl, cycloalkyl, cycloalkyl-oxy, heterocycloalkyl, aryl, aryl-oxy, aryl-alkoxy, heteroaryl, heteroaryl-amino, carboxyalkyl, carboxyalkenyl, carboxyalkyl-aryl, carboxyalkoxy-aryl, carboxyalkyl-heterocycloalkyl, carboxyalkenyl-heterocycloalkyl, carboxyalkoxy-heterocycloalkyl, carboxyalkyl-aminoaryl, carboxyalkyl-aryl-oxy or carboxyalkyl-heteroaryl; the alkyl, alkoxy, cycloalkyl, aryl, heterocycloalkyl, heteroaryl or heteroarylene is optionally substituted with one or more substituents selected from halo, -COOH, alkyl, alkoxy, haloalkyl, alkylsulfonyl and heteroaryl-alkyl; and the heterocycloalkyl, heteroaryl and heteroarylene include one or more heteroatoms selected from N, O and S. It exibits the activity of a diacylglycerol acyltransferase 2 (DGAT2) inhibitor. A pharmaceutical composition comprising same, and a use thereof.

IPC Classes  ?

  • C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
  • A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
  • C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

65.

ANTI-LILRB1 ANTIBODY AND USES THEREOF

      
Document Number 03161827
Status Pending
Filing Date 2020-12-22
Open to Public Date 2021-07-01
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Choi, Yoon Aa
  • Kim, Jung A
  • Jung, Saem
  • Lee, Ji Hyun
  • Na, Kyubong
  • Kim, Yeonchul
  • Kim, Han Byul

Abstract

The present invention relates to an anti-LILRB1 antibody having increased specificity for LILRB1, and to uses thereof. Specifically, provided are an anti-LILRB1 antibody or antigen-binding fragment thereof, and uses thereof in treating cancer.

IPC Classes  ?

  • C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

66.

FUSION POLYPEPTIDE COMPRISING GDF15 AND POLYPEPTIDE REGION CAPABLE OF O-GLYCOSYLATION

      
Document Number 03159979
Status Pending
Filing Date 2020-12-10
Open to Public Date 2021-06-17
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Kim, Yeonchul
  • Son, Young Dok
  • Na, Kyubong
  • Hong, Ji Ho
  • Jung, Saem
  • Jin, Myung Won
  • Park, Ji A
  • Noh, Soomin
  • Park, Hyuntaek

Abstract

Disclosed are: a fusion polypeptide comprising growth differentiation factor 15 (GDF15) and a polypeptide region capable of O-glycosylation; a pharmaceutical composition comprising the fusion polypeptide; and a method for increasing the in vivo duration of GDF15, comprising the step of fusing a polypeptide region capable of O-glycosylation.

IPC Classes  ?

  • C07K 14/475 - Growth factors; Growth regulators
  • A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment

67.

SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT

      
Document Number 03158593
Status Pending
Filing Date 2020-11-20
Open to Public Date 2021-06-10
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Paek, Seung Yup
  • Park, Deok Seong
  • Hong, Sang Yong

Abstract

The present invention relates to a compound of the following general formulawhich functions as a sphingosine-l-phosphate receptor agonist useful for treating autoimmune disorders. Also provided is a preparation method therefor, a pharmaceutical composition containing the same as an active ingredient, and a use thereof. The compound according to the present invention has effect in extensive autoimmune diseases and chronic inflammatory diseases, including relapsing-remitting multiple sclerosis, and can also be used for treating or preventing immunoregulatory disorders.

IPC Classes  ?

  • C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
  • A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
  • A61K 31/4439 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
  • A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
  • A61P 25/00 - Drugs for disorders of the nervous system
  • A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
  • A61P 37/00 - Drugs for immunological or allergic disorders
  • C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

68.

MELANOCORTIN-4 RECEPTOR AGONISTS

      
Document Number 03135543
Status In Force
Filing Date 2020-11-06
Open to Public Date 2021-05-14
Grant Date 2023-08-01
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Kang, Seung Wan
  • Park, Hee Dong
  • Park, Hee Dong
  • Yeo, Su Jin
  • Park, Hyun Seo
  • Hong, Ji Ho
  • Ahn, Hye Won
  • Choi, Eun Sil

Abstract

The present invention relates to a compound exhibiting excellent agonist activity against melanocortin receptors. More specifically, the present invention relates to a compound of Formula 1, a pharmaceutical composition comprising the compound as an active ingredient, and a use thereof, and the compound of the present invention exhibits excellent agonist activity against melacortin-4 receptors and can be particularly useful in preventing or treating obesity, diabetes, inflammation and erectile dysfunction.

IPC Classes  ?

  • C07D 207/16 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
  • A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim

69.

NEONATAL FC RECEPTOR BINDING AFFIMERS

      
Document Number 03155082
Status Pending
Filing Date 2020-10-16
Open to Public Date 2021-04-22
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Kim, Yeonchul
  • Lee, Jaehyung
  • Jung, Saem
  • Lee, Joon Hee
  • Park, Gyeong Hyae
  • Na, Kyubong
  • Matthew, Vincent
  • Amrik, Basran
  • Emma, Stanley
  • Emma, Jenkins
  • Estelle, Adam

Abstract

Provided herein, in some embodiments, are AFFIMER® polypeptides that binds to the neonatal Fc receptor (FcRn) and extends the half-life of the polypeptides. Also provided herein, in some embodiments, are compositions containing the polypeptides, methods of using the polypeptides, and methods of producing the polypeptides.

IPC Classes  ?

  • C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
  • A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
  • A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
  • C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
  • C07K 14/735 - Fc receptors
  • C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
  • C07K 19/00 - Hybrid peptides
  • C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
  • C12N 15/12 - Genes encoding animal proteins
  • C12N 15/62 - DNA sequences coding for fusion proteins
  • C12N 15/63 - Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression

70.

FUSION POLYPEPTIDE COMPRISING FC REGION OF IMMUNOGLOBULIN AND GDF15

      
Document Number 03136969
Status Pending
Filing Date 2020-04-22
Open to Public Date 2020-10-29
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Kim, Yeonchul
  • Min, Kyeongsik
  • Son, Young Dok
  • Na, Kyubong
  • Hong, Ji Ho
  • Jung, Saem
  • Jin, Myung Won
  • Park, Ji A
  • Noh, Soomin

Abstract

Disclosed are: a fusion polypeptide comprising growth/differentiation factor 15 (GDF15) and an Fc region of an immunoglobulin; a pharmaceutical composition comprising the fusion polypeptide; and a method for increasing the in vivo duration of GDF15, the method comprising a step for fusing an Fc region of an immunoglobulin.

IPC Classes  ?

  • C07K 14/475 - Growth factors; Growth regulators
  • A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
  • A61K 38/18 - Growth factors; Growth regulators
  • A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
  • A61P 3/04 - Anorexiants; Antiobesity agents
  • A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

71.

POLYETHYLENE HAVING HIGH DEGREE OF CROSSLINKING AND CROSSLINKED POLYETHYLENE PIPE COMPRISING THE SAME

      
Document Number 03128864
Status Pending
Filing Date 2020-02-20
Open to Public Date 2020-08-27
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Cho, Sol
  • Lee, Hyunsup
  • Kim, Sun Mi
  • Choi, Yi Young
  • Lee, Myunghan
  • Kim, Yeonsoo

Abstract

The present invention relates to polyethylene having a high degree of cross-linking, and a cross-linked polyethylene pipe comprising the same. The polyethylene according to the present invention has an ultra-high molecular weight so as to have increased cross-linking speed, thereby exhibiting a sufficient degree of cross-linking even when cross-linking time is short, and thus can exhibit excellent strength and pressure resistance.

IPC Classes  ?

  • C08F 10/02 - Ethene
  • C08F 2/38 - Polymerisation using regulators, e.g. chain terminating agents
  • C08F 4/646 - Catalysts comprising at least two different metals, in metallic form or as compounds thereof, in addition to the component covered by group
  • C08F 4/659 - Component covered by group containing a transition metal-carbon bond
  • C08F 4/6592 - Component covered by group containing a transition metal-carbon bond containing at least one cyclopentadienyl ring, condensed or not, e.g. an indenyl or a fluorenyl ring
  • C08K 5/00 - Use of organic ingredients
  • C08K 5/14 - Peroxides
  • C08L 23/06 - Polyethene
  • F16L 9/12 - Rigid pipes of plastics with or without reinforcement

72.

CROSSLINKED POLYETHYLENE PIPE HAVING EXCELLENT PHYSICAL PROPERTIES

      
Document Number 03128865
Status Pending
Filing Date 2020-02-20
Open to Public Date 2020-08-27
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Lee, Hyunsup
  • Cho, Sol
  • Kim, Yeonsoo
  • Choi, Yi Young
  • Lee, Myunghan

Abstract

The present disclosure relates to a crosslinked polyethylene pipe having excellent physical properties. The crosslinked polyethylene pipe according to the present disclosure has optimized the degree of crosslinking and storage modulus by finding out the optimum physical property range between the degree of crosslinking and the storage modulus which have a mutual trade-off relationship, whereby the crosslinked polyethylene pipe according to the present disclosure has excellent long-term durability and short-term pressure resistance, and thus can be applied to various fields requiring these physical properties.

IPC Classes  ?

73.

POLYETHYLENE HAVING HIGH PRESSURE RESISTANCE AND CROSSLINKED POLYETHYLENE PIPE COMPRISING THE SAME

      
Document Number 03123238
Status Pending
Filing Date 2020-02-20
Open to Public Date 2020-08-27
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Cho, Sol
  • Lee, Hyunsup
  • Kim, Sun Mi
  • Choi, Yi Young
  • Lee, Myunghan
  • Kim, Yeonsoo

Abstract

The present disclosure relates to a polyethylene having high pressure resistance and a crosslinked polyethylene pipe including the same. The polyethylene according to the present disclosure has high melt index and density and exhibits a sufficient degree of crosslinking, thereby exhibiting excellent strength and pressure resistance characteristics.

IPC Classes  ?

  • C08F 10/02 - Ethene
  • C08F 2/38 - Polymerisation using regulators, e.g. chain terminating agents
  • C08F 4/659 - Component covered by group containing a transition metal-carbon bond
  • C08F 4/6592 - Component covered by group containing a transition metal-carbon bond containing at least one cyclopentadienyl ring, condensed or not, e.g. an indenyl or a fluorenyl ring
  • C08K 5/00 - Use of organic ingredients
  • C08K 5/14 - Peroxides
  • C08L 23/06 - Polyethene
  • F16L 9/12 - Rigid pipes of plastics with or without reinforcement

74.

METHOD OF PREPARING ORGANIC ZINC CATALYST AND METHOD OF PREPARING POLYALKYLENE CARBONATE RESIN BY USING THE ORGANIC ZINC CATALYST PREPARED THEREBY

      
Document Number 03099972
Status Pending
Filing Date 2019-12-20
Open to Public Date 2020-06-25
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Kim, Sung Kyoung
  • Park, Seung Young
  • Shin, Sang Cheol
  • Min, Kyung Min

Abstract

The present invention relates to a method for preparing an organic zinc catalyst through solid phase mixing that does not require a solvent and a washing process, and a method for preparing a polyalkylene carbonate resin using the organic zinc catalyst prepared thereby.

IPC Classes  ?

75.

METHOD FOR SEPARATING ORGANIC ZINC CATALYST USING FILTRATION MEMBRANE

      
Document Number 03105028
Status Pending
Filing Date 2019-12-19
Open to Public Date 2020-06-25
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Min, Kyung Min
  • Kim, Sung Kyoung
  • Park, Seung Young
  • Shin, Sang Cheol

Abstract

The present invention relates to a method for separating an organic zinc catalyst dispersed in a polyalkylene carbonate resin solution by filtering the polyalkylene carbonate resin solution. When using the method for separating an organic zinc catalyst according to the resent invention, organic zinc catalyst particles are efficiently removed from a polyalkylene carbonate resin solution, so that a transparent, high-purity polyalkylene carbonate solution can be obtained.

IPC Classes  ?

  • B01D 67/00 - Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
  • B01D 69/12 - Composite membranes; Ultra-thin membranes
  • B01D 71/26 - Polyalkenes
  • C08G 64/34 - General preparatory processes using carbon dioxide and cyclic ethers
  • C08G 64/40 - Post-polymerisation treatment

76.

POLYALKYLENE CARBONATE-POLYLACTIC ACID COMPOSITE, METHOD OF PREPARING THE SAME, AND MOLDED ARTICLE PREPARED BY USING THE COMPOSITE

      
Document Number 03111763
Status Pending
Filing Date 2019-12-20
Open to Public Date 2020-06-25
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Kim, Sung Kyoung
  • Park, Seung Young

Abstract

The present invention relates to a polyalkylene carbonate-polylactic acid composite including non-halogen ether-based solvent in an amount of 0.1 wt% or less with improved mechanical properties as well as excellent transparency and flexibility, a method of preparing the same, and a molded article prepared by using the polyalkylene carbonate-polylactic acid composite.

IPC Classes  ?

  • C08L 69/00 - Compositions of polycarbonates; Compositions of derivatives of polycarbonates
  • C08J 3/09 - Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in organic liquids
  • C08L 67/02 - Polyesters derived from dicarboxylic acids and dihydroxy compounds
  • C08L 67/04 - Polyesters derived from hydroxy carboxylic acids, e.g. lactones

77.

FILLER COMPRISING HYALURONIC ACID HYDROGEL HAVING EXCELLENT FILLING PROPERTIES

      
Document Number 03121313
Status In Force
Filing Date 2019-12-19
Open to Public Date 2020-06-25
Grant Date 2023-07-18
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Jang, Cheol
  • Kim, Yeonsoo
  • Lee, Hyunsup
  • Lee, Myunghan
  • Kim, Ji Sun
  • Jung, Hyun Tae
  • So, Jineon
  • Lee, Chang Hyun
  • Ree, Hwayoun

Abstract

A hyaluronic acid hydrogel incorporating cross-linked hyaluronic acid is provided for cosmetic uses in alleviating the appearance of wrinkles and other skin conditions which are improved by adding volume to the affected tissues. The invented filler is characterized by a custom parameter value (WIE) related to its filling abilities, developed using microrheology technology. The invented filler thus exhibits improved high viscoelasticity flow properties, has low mobility when injected into skin while still maintaining the shape thereof, and thus has excellent soft tissue restoration properties, for example for the cheeks, breasts, nose, lips or bottom, and excellent volume expansion and wrinkle alleviation properties.

IPC Classes  ?

  • A61L 27/20 - Polysaccharides
  • A61F 2/00 - Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
  • A61L 2/00 - Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
  • A61L 27/52 - Hydrogels or hydrocolloids

78.

METHOD FOR REGENERATING WASTE ORGANIC ZINC CATALYST THROUGH SURFACE MODIFICATION

      
Document Number 03121629
Status In Force
Filing Date 2019-12-20
Open to Public Date 2020-06-25
Grant Date 2024-06-18
Owner LG CHEM, LTD. (Republic of Korea)
Inventor Kim, Sung Kyoung

Abstract

The present invention relates to a method for surface-modifying an organozinc catalyst with a dicarboxylic acid and a zinc compound and regenerating same. When the method for regenerating an organozinc catalyst, of the present invention, is used, an organozinc catalyst can be regenerated by a simple method of performing modification by alternately and repeatedly using a dicarboxylic acid and a zinc compound.

IPC Classes  ?

79.

FILLER HAVING EXCELLENT FILLER PROPERTIES COMPRISING HYALURONIC ACID HYDROGEL

      
Document Number 03122116
Status In Force
Filing Date 2019-12-19
Open to Public Date 2020-06-25
Grant Date 2023-07-18
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Jang, Cheol
  • Lee, Chung
  • Kim, Ji Sun
  • Jung, Hyun Tae
  • Lee, Chang Hyun
  • So, Jineon
  • Ree, Hwayoun

Abstract

The present invention relates to a filler comprising a hyaluronic acid hydrogel having a lift value in a specific range relative to the unit amount (w/w%) of hyaluronic acid included in a filler, in contrast to the modification degree, and as a result of having said lift value the filler exhibits improved high viscoelasticity flow properties, has the advantages of both monophasic and biphasic hyaluronic acid hydrogel fillers, and thus exhibits good tissue-restoring properties, has low mobility when injected into skin whilst still maintaining the shape thereof for a long time, and has minimized deformation of the hyaluronic acid through the minimization of the use of crosslinkers, and thus the natural form of hyaluronic acid molecules can be maintained, enabling a reduction in the occurrence of immune reactions and side effects, and thus has excellent soft tissue restoration properties, volume expansion properties and wrinkle alleviation properties.

IPC Classes  ?

  • A61L 27/20 - Polysaccharides
  • A61F 2/00 - Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
  • A61K 8/73 - Polysaccharides
  • A61L 2/00 - Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
  • A61L 27/52 - Hydrogels or hydrocolloids
  • A61Q 19/08 - Anti-ageing preparations

80.

PLASTICIZER COMPOSITION AND RESIN COMPOSITION COMPRISING THE SAME

      
Document Number 03097991
Status Pending
Filing Date 2019-08-23
Open to Public Date 2020-03-05
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Kim, Hyun Kyu
  • Moon, Jeong Ju
  • Choi, Woo Hyuk
  • Cho, Yun Ki
  • Kim, Joo Ho
  • Jeong, Seok Ho

Abstract

The present invention relates to a plasticizer composition comprising: two or more terephthalates which are identical-carbon number types whereby the carbon numbers of alkyl groups bound to two ester groups are identical to each other; and one or more terephthalate which is a different-carbon number type whereby the carbon numbers of alkyl groups bound to two ester groups are different from each other, wherein the different-carbon number type comprises both a higher alkyl and a lower alkyl, the higher alkyl being selected from alkyl having a carbon number of at most 8, and the lower alkyl being selected from alkyl having a carbon number of at least 5. When applied to a resin, the plasticizer composition may improve effects such as viscosity stability, migration resistance and stress tolerance, and may enable plasticization efficiency and mechanical properties to be maintained at and improved by the same level or higher.

IPC Classes  ?

  • C08K 5/101 - Esters; Ether-esters of monocarboxylic acids
  • C08K 5/00 - Use of organic ingredients
  • C08L 101/00 - Compositions of unspecified macromolecular compounds

81.

HYALURONIC ACID FILLER HAVING HIGH LIFT CAPACITY AND LOW INJECTION FORCE

      
Document Number 03106381
Status In Force
Filing Date 2019-07-09
Open to Public Date 2020-01-16
Grant Date 2024-02-13
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Jang, Cheol
  • Kim, Ji Sun
  • So, Jineon
  • Lee, Chang Hyun
  • Lee, Chung
  • Ree, Hwayoun
  • Jung, Hyun Tae

Abstract

A hyaluronic acid filler according to the present invention not only exhibits an improved high lift capacity so as to maintain the shape of the skin for a long period of time while having a low probability for movement when injected into the skin, but also has a very low injection pressure during injection so as to reduce wrinkles and restore or expand the volume of soft tissues such as that of the cheeks, breasts, nose, lips, and buttocks, and is excellent when used for contour correction. Even when crosslinking agents are used sparingly in the manufacturing process, the hyaluronic acid filler has increased residence time in the human body and causes patients less pain.

IPC Classes  ?

  • A61L 27/20 - Polysaccharides
  • A61F 2/00 - Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61L 27/52 - Hydrogels or hydrocolloids
  • C08L 5/08 - Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof

82.

PLASTICIZER COMPOSITION COMPRISING CYCLOHEXANE POLYESTER-BASED SUBSTANCE AND RESIN COMPOSITION COMPRISING THE SAME

      
Document Number 03086858
Status Pending
Filing Date 2019-07-03
Open to Public Date 2020-01-16
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Kim, Hyun Kyu
  • Moon, Jeong Ju
  • Choi, Woo Hyuk

Abstract

Provided is a plasticizer composition to which a cyclohexane polyester-based substance is applied as a plasticizer in combination with a perhydride having a smaller number of ester groups than the cyclohexane polyester-based substance, so that volatile loss, thermal stability, and mechanical properties such as an elongation rate and tensile strength are improved.

IPC Classes  ?

  • C08K 5/00 - Use of organic ingredients
  • C08K 5/12 - Esters; Ether-esters of cyclic polycarboxylic acids
  • C08L 101/00 - Compositions of unspecified macromolecular compounds

83.

HYALURONIC ACID FILLER HAVING HIGH VISCOELASTICITY AND HIGH COHESIVENESS

      
Document Number 03105709
Status In Force
Filing Date 2019-07-08
Open to Public Date 2020-01-09
Grant Date 2024-03-12
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Jang, Cheol
  • Lee, Chung
  • Kim, Ji Sun
  • Jung, Hyun Tae
  • Lee, Chang Hyun
  • So, Jineon
  • Ree, Hwayoun

Abstract

A hyaluronic acid filler according to the present invention shows improved high viscoelastic flow characteristics, thus exhibiting the advantages of both a monophasic hyaluronic acid filler and a biphasic hyaluronic acid filler, such that when injected into the skin, the hyaluronic acid filler can retain a shape for a long time with low mobility, thereby reducing wrinkles, and repairing or enlarging the volume of soft tissues, such as cheeks, breasts, nose, lips, and buttocks. Furthermore, the hyaluronic acid filler can be suitably used in contour correction, and even when prepared by using a small amount of a cross-linking agent during the preparation process, can increase the retention time in a human body with negligible side effects.

IPC Classes  ?

  • A61L 27/20 - Polysaccharides
  • A61F 2/00 - Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61L 27/52 - Hydrogels or hydrocolloids
  • A61L 27/54 - Biologically active materials, e.g. therapeutic substances
  • C08L 5/08 - Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof

84.

PLASTICIZER COMPOSITION AND RESIN COMPOSITION INCLUDING THE SAME

      
Document Number 03098588
Status Pending
Filing Date 2019-06-03
Open to Public Date 2019-12-19
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Kim, Hyun Kyu
  • Cho, Yun Ki
  • Choi, Woo Hyuk
  • Moon, Jeong Ju
  • Kim, Joo Ho
  • Jeong, Seok Ho

Abstract

The present invention relates to a plasticizer composition which comprises cyclohexane-1,2-diester material represented by chemical formula 1, and a trimellitate material represented by chemical formula 2, the plasticizer composition being environmentally friendly whilst having excellent stability and basic physical properties.

IPC Classes  ?

  • C08K 5/00 - Use of organic ingredients
  • C08K 5/11 - Esters; Ether-esters of acyclic polycarboxylic acids
  • C08K 5/12 - Esters; Ether-esters of cyclic polycarboxylic acids
  • C08K 5/1515 - Three-membered rings
  • C08L 101/00 - Compositions of unspecified macromolecular compounds

85.

COMPOUND EXHIBITING ENTEROPEPTIDASE INHIBITORY ACTIVITY

      
Document Number 03099268
Status In Force
Filing Date 2019-05-08
Open to Public Date 2019-11-14
Grant Date 2023-03-07
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Kim, Young Kwan
  • Kwon, Ohhwan
  • Park, Heedong
  • Park, Junggyu
  • Choi, Hwan Geun
  • Son, Jung Beom
  • Ko, Eunhwa
  • Kim, So Young
  • Lee, Seungyeon
  • Kang, Seock Yong
  • Ko, Yi Kyung
  • Park, Jin-Hee

Abstract

The present invention relates to a beneficial compound as exemplified below, which exhibits enteropeptidase-inhibiting activity, a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the compound or pharmaceutically acceptable salt, for use in preventing and treating metabolic diseases such as obesity, diabetes mellitus or hyperlipidemia. (see above formula) The compound of the present invention has excellent inhibitory activity against enteropeptidase, and is not absorbed into the body. Rather, it is excreted outside the body, along with fat and protein. Since not only fat but also protein are discharged together, this compound results in fewer side effects such as fatty stools. As well, because the compound acts only in the gastrointestinal tract, it has fewer side effects such as depression. It has use as a therapeutic or prophylactic drug for various metabolic diseases such as obesity, diabetes mellitus, and hyperlipidemia.

IPC Classes  ?

  • C07D 277/82 - Nitrogen atoms
  • A61K 31/426 - 1,3-Thiazoles
  • A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
  • A61K 31/428 - Thiazoles condensed with carbocyclic rings
  • A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
  • A61P 3/04 - Anorexiants; Antiobesity agents
  • A61P 3/06 - Antihyperlipidemics
  • A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
  • C07D 277/42 - Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
  • C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond

86.

PLASTICIZER COMPOSITION AND RESIN COMPOSITION INCLUDING THE SAME

      
Document Number 03077345
Status Pending
Filing Date 2018-12-04
Open to Public Date 2019-06-13
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Kim, Hyun Kyu
  • Moon, Jeong Ju
  • Cho, Yun Ki
  • Kim, Joo Ho
  • Jeong, Seok Ho

Abstract

The present invention relates to a plasticizer composition and a resin composition comprising the same. The plasticizer composition comprises: a terephthalate-based material comprising dibutyl terephthalate, butyl(2-ethylhexyl) terephthalate and di(2-ethylhexyl) terephthalate; and a glyceride-based material, and the plasticizer composition can improve mechanical properties such as tensile strength, elongation and modulus and can maintain the characteristics of a terephthalate-based material having excellent transmittance, transparency and migration loss characteristics.

IPC Classes  ?

  • C08K 5/00 - Use of organic ingredients
  • C08K 5/101 - Esters; Ether-esters of monocarboxylic acids
  • C08K 5/103 - Esters; Ether-esters of monocarboxylic acids with polyalcohols
  • C08L 101/00 - Compositions of unspecified macromolecular compounds

87.

POLYALKYLENE CARBONATE RESIN COMPOSITION AND POLYALKYLENE CARBONATE RESIN MOLDED ARTICLE

      
Document Number 03044799
Status In Force
Filing Date 2017-12-27
Open to Public Date 2018-07-05
Grant Date 2024-01-02
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Park, Seung Young
  • Kim, Sung-Kyoung

Abstract

The present invention relates to a polyalkylene carbonate resin composition and, more specifically, to a polyalkylene carbonate resin composition containing a polyalkylene carbonate and a polyketone, having excellent transparency, flexibility, and mechanical and chemical properties, and exhibiting, especially, excellent thermal stability.

IPC Classes  ?

  • C08L 69/00 - Compositions of polycarbonates; Compositions of derivatives of polycarbonates
  • C08G 64/02 - Aliphatic polycarbonates
  • C08L 73/00 - Compositions of macromolecular compounds obtained by reactions forming a linkage containing oxygen or oxygen and carbon in the main chain, not provided for in groups ; Compositions of derivatives of such polymers

88.

ASPHALT MODIFIER AND ASPHALT COMPOSITION COMPRISING THE SAME

      
Document Number 03003844
Status In Force
Filing Date 2016-12-22
Open to Public Date 2018-04-26
Grant Date 2023-07-04
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Kim, Tae Jung
  • Lee, Chun Hwa
  • Lee, Hye Rim

Abstract

The present invention relates to an asphalt modifier and an asphalt composition comprising the same, wherein the asphalt composition comprises a vinyl aromatic hydrocarbon-conjugated diene block copolymer as a main chain, and more specifically, when a vinyl aromatic hydrocarbon-conjugated diene block copolymer comprising a particular polyfunctional functional group is used as an asphalt modifier, the asphalt modifier has excellent compatibility with the asphalt composition, and thus effectively improves low-temperature physical properties, high-temperature physical properties, storage stability, and the like of the asphalt composition.

IPC Classes  ?

  • C08L 53/02 - Compositions of block copolymers containing at least one sequence of a polymer obtained by reactions only involving carbon-to-carbon unsaturated bonds; Compositions of derivatives of such polymers of vinyl aromatic monomers and conjugated dienes
  • C08F 2/44 - Polymerisation in the presence of compounding ingredients, e.g. plasticisers, dyestuffs, fillers
  • C08F 297/04 - Macromolecular compounds obtained by successively polymerising different monomer systems using a catalyst of the ionic or coordination type without deactivating the intermediate polymer using a catalyst of the anionic type polymerising vinyl aromatic monomers and conjugated dienes
  • C08K 5/54 - Silicon-containing compounds
  • C08L 95/00 - Compositions of bituminous materials, e.g. asphalt, tar or pitch

89.

BIARYL DERIVATIVE AS GPR120 AGONIST

      
Document Number 03121986
Status In Force
Filing Date 2015-12-23
Open to Public Date 2016-06-30
Grant Date 2024-04-09
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Kim, Young Kwan
  • Park, Sang Yun
  • Joo, Hyun Woo
  • Choi, Eun Sil
  • Paek, Seung Yup
  • Kang, Seung Wan
  • Kim, Byung Gyu
  • Lee, Chang Seok
  • Kim, Sung Wook
  • Lee, Sang Dae

IPC Classes  ?

  • C07D 213/70 - Sulfur atoms
  • A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
  • A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
  • A61K 31/33 - Heterocyclic compounds
  • A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
  • A61K 31/36 - Compounds containing methylenedioxyphenyl groups, e.g. sesamin
  • A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
  • A61K 31/44 - Non-condensed pyridines; Hydrogenated derivatives thereof
  • A61K 31/4418 - Non-condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
  • A61K 31/4439 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
  • A61K 31/444 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
  • A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
  • A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
  • A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
  • A61P 3/00 - Drugs for disorders of the metabolism
  • A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
  • C07C 59/68 - Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
  • C07C 229/44 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by unsaturated carbon chains
  • C07D 213/64 - One oxygen atom attached in position 2 or 6
  • C07D 235/16 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
  • C07D 307/79 - Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
  • C07D 317/54 - Radicals substituted by oxygen atoms
  • C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
  • C07D 401/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
  • C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
  • C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
  • C07D 417/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings

90.

BIARYL DERIVATIVE AS GPR120 AGONIST

      
Document Number 02970011
Status In Force
Filing Date 2015-12-23
Open to Public Date 2016-06-30
Grant Date 2021-08-03
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Kim, Young Kwan
  • Park, Sang Yun
  • Joo, Hyun Woo
  • Choi, Eun Sil
  • Paek, Seung Yup
  • Kang, Seung Wan
  • Kim, Byung Gyu
  • Lee, Chang Seok
  • Kim, Sung Wook
  • Lee, Sang Dae

Abstract

The present invention relates to a biaryl derivative expressed by the chemical formula 1, a method for producing the biaryl derivative, a pharmaceutical composition comprising same, and use of same, the biaryl derivative expressed by the chemical formula 1, as a GPR120 agonist, promoting GLP-1 generation in the gastro-intestinal tract, reducing insulin resistance in the liver, muscles and the like from anti-inflammatory activity in the macrophage, pancreatic cells and the like, and allowing effective use in prevention or treatment of inflammation or metabolic diseases such as diabetes, complications from diabetes, obesity, non-alcoholic fatty liver disease, fatty liver disease, and osteoporosis.

IPC Classes  ?

  • C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
  • A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
  • A61P 3/04 - Anorexiants; Antiobesity agents
  • A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

91.

CROSSLINKED POLYETHYLENE RESIN COMPOSITION

      
Document Number 02908265
Status In Force
Filing Date 2015-03-25
Open to Public Date 2016-05-19
Grant Date 2018-11-13
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Sun, Ka Ram
  • Park, In Gyu
  • Nam, Youn Sun
  • Song, Young Il

Abstract

Disclosed is a crosslinked polyethylene resin composition. More particularly, disclosed is a crosslinked polyethylene resin composition comprising a) 100 parts by weight of low-density polyethylene (LDPE), b) 0.1 to 10 parts by weight of a crosslinking agent, c) 0.1 to 5 parts by weight of a crosslinking facilitator, d) 0 to 5 parts by weight of a treeing inhibitor, and e) greater than 0.3 parts by weight and 5 parts by weight or less of an antioxidant. According to the present disclosure, a crosslinked polyethylene resin composition having general allowance temperature due to excellent heat resistance characteristics, enhanced long-term workability due to superior long-term, aging resistance, and water tree inhibition effects similar or better than those of conventional crosslinked polyethylene (XLPE)), and a power cable manufactured from the composition may be provided.

IPC Classes  ?

92.

METHOD FOR MODULATING GALACTOSYLATION OF RECOMBINANT PROTEIN THROUGH OPTIMIZATION OF CULTURE MEDIUM

      
Document Number 02943667
Status In Force
Filing Date 2015-01-29
Open to Public Date 2015-08-06
Grant Date 2022-11-08
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Jung, Jun
  • Song, Won Seok
  • Lee, Jun Eok
  • Kim, Yeon Chul

Abstract

The present invention relates to: a method for preparing a target recombinant protein of which the galactosylation is controlled or a method for controlling the galactosylation of a target recombinant protein, comprising a step of increasing the osmotic pressure of a culture solution of animal cells, which express a target recombinant protein, during the culturing of the animal cells; a method for preparing a target recombinant protein of which the galactosylation is controlled or a method for controlling the galactosylation of a target recombinant protein, comprising a step of supplementing asparagine to a culture solution of animal cells, which express a target recombinant protein, during the culturing of the animal cells; a method for preparing a target recombinant protein of which the galactosylation is controlled or a method for controlling the galactosylation of a target recombinant protein, comprising a step of increasing the osmotic pressure of a culture solution of animal cells, which express a target recombinant protein, and supplementing asparagine thereto during the culturing of the animal cells; and a target recombinant protein of which the galactosylation is controlled, which is prepared by the method.

IPC Classes  ?

  • C12N 5/02 - Propagation of single cells or cells in suspension; Maintenance thereof; Culture media therefor
  • C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
  • C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans

93.

BIARYL DERIVATIVES AS GPR120 AGONISTS

      
Document Number 02912747
Status In Force
Filing Date 2014-06-26
Open to Public Date 2014-12-31
Grant Date 2021-05-04
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Kim, Young Kwan
  • Park, Sang Yun
  • Joo, Hyun Woo
  • Choi, Eun Sil

Abstract

CA 2912747 2017-05-10 [ABSTRACT] The present invention relates to biaryl derivatives of Formula 1, a method for preparing the same, a pharmaceutical composition comprising the same and use thereof. The biaryl derivatives of Formula 1 according to the present invention may promote GLP- 1 formation in the gastrointestinal tract and improve insulin resistance in the liver or in muscle due to anti-inflammatory action in macrophages, lipocytes, etc., and may therefore be useful used for preventing or treating diabetes, complications of diabetes, obesity, non-alcoholic fatty liver, steatohepatitis, osteoporosis or inflammation. [Formula 1] ¨ D (R4)r) R2¨ E A B G ¨ COOR7 (R3)rn wherein, A, B, D, E, G, RI, R2, R3, Itt, R7, m and n are as defined herein. I'

IPC Classes  ?

  • C07D 213/30 - Oxygen atoms
  • A61K 31/4412 - Non-condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
  • A61P 3/00 - Drugs for disorders of the metabolism
  • A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

94.

PHARMACEUTICAL COMPOSITION FOR INHIBITING IMMUNE RESPONSE THROUGH INDUCING DIFFERENTIATION INTO REGULATOR T CELLS AND PROMOTING PROLIFERATION OF REGULATOR T CELLS

      
Document Number 02907574
Status In Force
Filing Date 2014-03-25
Open to Public Date 2014-10-02
Grant Date 2017-09-05
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Cho, Seok Goo
  • Kim, Na Youn
  • Kim, Eun Jung
  • Im, Keon Il
  • Lim, Jung Yeon
  • Jeon, Eun Joo

Abstract

The present invention relates to new medical use of (tetrahydropyran-4-yl)-[2-phenyl-5-(1,1-dioxo-thiomorpholine-4-yl)methyl-1H-indol-7-yl]amine, and more particularly, to a pharmaceutical composition containing the compound as an active ingredient, which is used for inhibiting an immune response, and/or for inducing differentiation into regulator T cells from undifferentiated T cells and/or promoting proliferation of regulator T cells.

IPC Classes  ?

  • A61K 31/404 - Indoles, e.g. pindolol
  • A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

95.

GPR40 RECEPTOR AGONIST, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT

      
Document Number 02889505
Status In Force
Filing Date 2013-11-08
Open to Public Date 2014-05-15
Grant Date 2020-12-29
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Lee, Sung Bae
  • Paek, Seung Yup
  • Yoon, Sook Kyung
  • Yoon, Seung Hyun
  • Choi, Jeung Soon

Abstract

The present invention relates to a novel compound having GPR40 receptor agonist activity that promotes insulin secretion and inhibits blood sugar rise after glucose loading, and is thereby useful for the treatment of diabetes and complications thereof, the preparation method thereof and pharmaceutical composition containing them as an active ingredient.

IPC Classes  ?

  • C07D 231/56 - Benzopyrazoles; Hydrogenated benzopyrazoles
  • A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K 31/404 - Indoles, e.g. pindolol
  • A61K 31/416 - 1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
  • A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
  • A61K 31/4192 - 1,2,3-Triazoles
  • A61K 31/422 - Oxazoles not condensed and containing further heterocyclic rings
  • A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
  • A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
  • A61K 31/4439 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
  • A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
  • A61K 31/505 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
  • C07D 209/04 - Indoles; Hydrogenated indoles
  • C07D 235/04 - Benzimidazoles; Hydrogenated benzimidazoles
  • C07D 249/18 - Benzotriazoles
  • C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
  • C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
  • C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
  • C07D 409/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
  • C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
  • C07D 471/04 - Ortho-condensed systems

96.

ADHESIVE TAPE FOR CAR

      
Document Number 02851479
Status In Force
Filing Date 2012-10-11
Open to Public Date 2013-04-18
Grant Date 2017-03-28
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Jang, Ae Jung
  • Kim, Jang Soon
  • Yoo, Seung Min

Abstract

The present invention provides a pressure sensitive adhesive tape comprising: an acrylic foam layer; and rubber-based adhesive layers which are formed on both sides of said acrylic foam layer, wherein the content of gel in said rubber-based adhesive layers is 40% or more. Furthermore, in order to accomplish the object of the present invention, a method for manufacturing a pressure sensitive adhesive layer is provided, and the method comprises the steps of: manufacturing an acrylic foam layer; and forming rubber-based adhesive layers on one side or both sides of said acrylic foam layer, wherein said step of forming the rubber-based adhesive layers comprises the steps of: manufacturing a styrene block copolymer; forming rubber-based adhesive layers by adding an adhesive additive and a plasticizer to said styrene block copolymer; and setting the content of gel in said rubber-based adhesive layers to 40% or more.

IPC Classes  ?

97.

STABLE LIQUID FORMULATION OF ETANERCEPT

      
Document Number 02837176
Status In Force
Filing Date 2012-06-01
Open to Public Date 2012-12-06
Grant Date 2017-05-16
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Choi, Suk Young
  • Ko, Youn Kyung
  • So, Jin Eon

Abstract

The present invention relates to a stable liquid formulation of etanercept (recombinant p75 sTNFR:Fc fusion protein), and more particularly, to a liquid formulation comprising one or more stabilizers selected from the group consisting of methionine, lysine, histidine, and pharmaceutically acceptable salts thereof in an amount sufficient to reduce by-product formation of etanercept during storage. The liquid formulation according to the present invention effectively reduces production of etanercept by-products and to stably maintain its pharmaceutical efficacies for long-term storage. Therefore, the reconstitution procedure is not required before administration, and the sterile formulation can be administered to patients to ensure patient safety. Thus, it can be applied to the fields in need of etanercept treatment.

IPC Classes  ?

  • A61K 9/08 - Solutions
  • A61K 31/195 - Carboxylic acids, e.g. valproic acid having an amino group
  • A61K 31/198 - Alpha-amino acids, e.g. alanine, edetic acid (EDTA)
  • A61K 31/4172 - Imidazole-alkanecarboxylic acids, e.g. histidine

98.

HYDRATE OF 1-{(2S)-2-AMINO-4-[2,4-BIS(TRIFLUOROMETHYL)-5,8-DIHYDROPYRIDO[3,4-D]PYRIMIDIN-7(6H)-YL]-4-OXOBUTYL}-5,5-DIFLUOROPIPERIDIN-2-ONE TARTRATE

      
Document Number 02814357
Status In Force
Filing Date 2011-10-31
Open to Public Date 2012-05-10
Grant Date 2015-07-07
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Park, Ki Sook
  • Yun, Jung Min
  • Kim, Bong Chan
  • Kim, Kyu Young
  • Lee, Ji Hye

Abstract

The present invention relates to 1.5 hydrate of of 1-{(2S)-2-amino-4-[2,4-bis(trifluoromethyl)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl]-4-oxobutyl}-5,5-difluoropiperidin-2-one tartrate, a process for preparing the same, and a pharmaceutical composition for inhibiting DPP-IV, which comprises said compound as the active component.

IPC Classes  ?

  • C07D 471/04 - Ortho-condensed systems
  • A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
  • A61P 3/04 - Anorexiants; Antiobesity agents
  • A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

99.

NON-AQUEOUS OILY INJECTABLE FORMULATION EXHIBITING PRESERVATIVE EFFICACY

      
Document Number 02811526
Status In Force
Filing Date 2011-09-09
Open to Public Date 2012-03-22
Grant Date 2018-05-08
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • So, Jin Eon
  • Yeo, Dong Jun
  • Jang, Yoon-Seon

Abstract

Disclosed herein is preferably a multi-dose type non-aqueous oily injectable formulation including; an active ingredient (drug) expressing therapeutic effects, which is dissolved, dispersed or suspended in a therapeutically effective amount, in oil. The disclosed non-aqueous oily injectable formulation may include; an oil-affinitive preservative, and a hydrophilic excipient non-phase separable from the oil-affinitive preservative when the excipient is mixed with the oil-affinitive preservative.

IPC Classes  ?

100.

METHOD OF PREPARING 3-AMINO-4-(2-OXO-PIPERIDIN-1-YL)-BUTYRIC ACID DERIVATIVE FOR SYNTHESIZING MEDICAMENT

      
Document Number 02810393
Status In Force
Filing Date 2011-08-25
Open to Public Date 2012-03-08
Grant Date 2016-04-12
Owner LG CHEM, LTD. (Republic of Korea)
Inventor
  • Kim, Bong Chan
  • Kim, Kyu Young
  • Lee, Hee Bong
  • An, Ji Eun
  • Lee, Kyu Woong

Abstract

The present invention relates to a novel method for preparing a compound of formula (2) as the intermediate, which can be effectively used for preparation of a compound of formula (1) exhibiting good inhibitory activity against dipeptidyl peptidase IV enzyme.

IPC Classes  ?

  • C07D 211/36 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • A61K 31/45 - Non-condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
  • A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
  • C07D 471/04 - Ortho-condensed systems
  1     2        Next Page